Based on my review of the reliable and credible scientific literature regarding articular cartilage biochemistry and physiology, cartilage degeneration, degenerative joint disease and osteoarthritis, I conclude that there is significant scientific agreement in support of the following health claims:
1. Glucosamine may reduce the risk of osteoarthritis.
2. Chondroitin sulfate may reduce the risk of osteoarthritis.
3. Glucosamine and chondroitin sulfate may reduce the risk of osteoarthritis.
4. Glucosamine may reduce the risk of osteoarthritis-related joint pain, tenderness and swelling.
5. Chondroitin sulfate may reduce the risk of osteoarthritis-related joint pain, tenderness and swelling.
6. Glucosamine and chondroitin sulfate may reduce the risk of osteoarthritis-related joint pain, tenderness and swelling.
7. Glucosamine may reduce the risk of joint degeneration.
8. Chondroitin sulfate may reduce the risk of joint degeneration.
9. Glucosamine and chondroitin sulfate may reduce the risk of joint degeneration. Glucosamine may reduce the risk of cartilage deterioration.
10. Chondroitin sulfate may reduce the risk of cartilage deterioration.
11. Glucosamine and chondroitin sulfate may reduce the risk of cartilage deterioration.
Composition and Physiologic Functions of Articular Cartilage and the Biochemical and Physiologic Roles of D -Glucosamine and the Chondroitin Sulfates
Cartilage is composed of a complex extracellular matrix of collagen and elastic fibers within a hydrated gel of glycosaminoglycans and proteoglycans. This specialized network is stabilized by means of intermolecular and intramolecular cross-links that harness the swelling pressure exerted by the high concentration of negatively charged aggregates. 1 This accounts for more than 98% of the articular cartilage volume; cellular components constitute the remaining 2%. The interaction of these matrix components imparts the characteristic biomechanical properties of flexibility and resistance to compression. The collagen component of the cartilage matrix is relatively inert, but the other constituents, such as proteoglycans, undergo a distinct turnover process during which the catabolism and removal of molecules from the extracellular matrix is in balance with the synthesis and deposition of new molecules.2
Proteoglycans are large macromolecules consisting of multiple chains of glycosaminoglycan disaccharides and oligosaccharides attached to a central protein core that provide a framework for collagen and also bind water and cations, forming a viscous, elastic layer that lubricates and protects the cartilage tissue. The presence of these negatively charged aggregates imparts to the matrix of articular cartilage its strong affinity for water and is the most significant contributor to the biomechanical properties of cartilage. The glycosaminoglycans most common in human connective tissue include the disaccharides keratan sulfate, dermatan sulfate, heparin sulfate and chondroitin sulfate and the oligosaccharide, hyaluronan. They consist of amino sugars, which are repeating disaccharide units composed of a hexuronic acid ( D -glucuronic acid, iduronic acid, or L -galactose) and a hexosamine ( D -glucosamine or D -galactosamine). 3,4
The main disaccharide units of cartilage glycosaminoglycans are formed by the (1→3) linkage of D -glucuronic acid to N -acetylglucosamine; disaccharide units are linked by β(1→4) galactosamine links. The D -galactosamine residues are sulfated either in position 4 (as in chondroitin-4-sulfate) or 6 (as in chondroitin-6-sulfate). The sulfate groups, together with the carboxyl groups of D -glucuronic acid, are ionized at tissue pH, conferring to the chain a strong global electronegative charge. 5-10 Inadequate sulfate availability resulting in the production of undersulfated proteoglycans will reduce their electronegative charge and water carrying capacity. 11,12
Glucosamine (2-amino-2-deoxyalpha- D -glucose) is an aminomonosaccharide that serves as a substrate for the biosynthesis of chondroitin sulfate, hyaluronan, and other macromolecules located in the extracellular cartilage matrix. The conversion of L -glutamine and D -fructose-6-P to L -glutamate and D -glucosamine by L -glutamine- D -fructose-6-P amidotransferase (E.C. 188.8.131.52) is the rate-limiting step in proteoglycan synthesis. 13-15 This reaction may be bypassed if D -glucosamine is available within the cell cytoplasm. 16,17 Whatever its source, D -glucosamine is phosphorylated and the resulting D -glucosamine-6-P is acetylated to N -acetyl- D -glucosamine, the common precursor for the biosynthesis of keratan sulfate, dermatan sulfate, chondroitin sulfate and hyaluronan. 16,17
Chondroitin sulfate is a glycosaminoglycan that is polymerized into long, unbranched polysaccharide chains in which some of the constituent chondroitin moieties (composed of D -glucuronic acid and N -acetyl- D -glucosamine) are sulfated. 18Close control of chondroitin sulfate synthesis determines chain length, disaccharide composition and degree of sulfation, which vary with anatomic location, stage of development and age and are heterogeneous. 19-24 For example, the sulfation pattern of chondroitin disaccharides in normal human articular cartilage varies. The deeper layers of immature cartilage contain 4 times more sulfated residues than the upper regions of the immature tissue contain (as a result of polysulfation of some chondroitin residues in the extracellular matrix of the deeper regions). 19-21 All regions of the extracellular matrix of immature articular cartilage contain a smaller ratio of chondroitin-6-sulfate to chondroitin-4-sulfate than is typical of the extracellular matrix of articular cartilage in adults. 19-21
Chondroitin sulfate polymers are secreted into the extracellular matrix covalently bound to proteins, forming protein-polysaccharide complexes called proteoglycans. In a proteoglycan, about 100 chondroitin sulfate chains, each containing 50 to 60 disaccharide units of chondroitin sulfate, are covalently attached to a polypeptide backbone composed of over 2,000 amino acids (the serine-rich core protein with a molecular weight of 250,000 to 300,000 daltons). This covalent O -linkage occurs between a terminal D- xylose or D- galactose residue that had been added to the polysaccharide chain and a serine or threonine residue on the core protein, with one chondroitin sulfate chain per 20 or so amino acid residues. The total molecular weight of an individual proteoglycan monomer is 1,500,000 to 2,500,000 daltons. 5
One end of the core protein of a proteoglycan is non-covalently linked to a long polysaccharide filament of hyaluronan through a link protein; the connection is achieved by a globular region of the link protein that surrounds the terminal portion of the core protein and a stretch of 5 disaccharide units along the length of the hyaluronan chain. 25,26 There are two structurally related N-terminal globular domains, G1 and G2, of which only G1 (and not G2) is involved in the aggregation of proteoglycans with hyaluronan. The interglobular domain joining G1 and G2 contains proteinase-sensitive sequences which appear to be the key sites for cleavage during aggrecan turnover. 5 Approximately 100 core proteins are bound to an individual hyaluronan chain, at regular intervals of 300 A, forming a unit of aggrecan, the large molecular mass proteoglycan-hyaluronan aggregate predominant within the extracellular matrix of articular cartilage.
The hydrodynamic properties of this aggregate determine the load-bearing capacity of articular tissue. As the electronegative charges of aggrecan draw water into the tissue, a large osmotic swelling pressure is created that swells and expands the extracellular matrix. This pressure produces tension within the interlacing collagen network of the matrix; balance is achieved when tension in the collagen network prevents further entry of water. Articular cartilage tissue swollen with water expresses substantial compressive resilience and offers considerable resistance to fluid flow and redistribution of water. Fully hydrated articular cartilage tissue behaves as a stiff elastic polymer when exposed to sudden impact loading, with pressure-induced displacement of water from the matrix with little or no effect on matrix macromolecules (although sustained loads will produce slow inelastic deformation). Removal of loading allows re-entry of water and a return to the pre-loading high-tension equilibrium condition. 5,18,27-29
Age and the Composition of Articular Cartilage
In rabbits, fetal articular cartilage is softer than is adult articular cartilage because fetal articular cartilage contains a greater proportion of polysulfated chondroitin sulfates and therefore its water binding capacity is greater. 30 In rats, as age increases from birth to mature adulthood, the extent to which nonosteoarthritic articular cartilage extracellular matrix chondroitins are sulfated decreases significantly. 31 In dogs, increasing age is accompanied by significantly decreased chondroitin sulfate and proteoglycan content of articular cartilage and reduced aggregability of the remaining proteoglycans. 32 Similarly, calf articular cartilage proteoglycans are larger on average than are proteoglycans in nonosteoarthritic adult bovine articular cartilage (and contain larger chondroitin sulfate polymers). 33 In addition to decreasing average size of matrix proteoglycans and chondroitin polymers, the ratio of chondroitin 6-sulfate to chondroitin 4-sulfate in the extracellular matrix of articular cartilage increases with increasing age. 34
In humans, increasing age is accompanied by a decreasing proportion of chondroitin sulfates in the extracellular matrix of nonosteoarthritic articular cartilage 35 and increases in the ratio of chondroitin 6-sulfate to chondroitin 4-sulfate 36,37 and in the free glucosamine content of the tissue. 38 Furthermore, the average chondroitin sulfate content of individual articular cartilage proteoglycans decreases, impairing the ability of proteoglycans to aggregate spontaneously with hyaluronan. 39In addition, the ability of proteoglycans to aggregate spontaneously with hyaluronan is decreased as a result of an increased incidence of defect in the core protein of newly-synthesized proteoglycans. 40 Consequently, the aggrecan content of the extracellular matrix of articular cartilage in adults is significantly lower than that in children. 40
In “normal but aged” human chondrocytes (mean age of donor: 68.8 +/- 4.2 years), basal (unstimulated) synthesis of matrix-degrading stromelysin-1 and collagenase is significantly greater than in chondrocytes harvested from joints of “normal young adults” (mean age of donor: 28.6 +/- 7.1 years). Therefore, “aging” may sensitize chondrocytes to the effects of accelerators of extracellular matrix degradation and may increase the requirement of chondrocytes for exogenous substrate to support the synthesis of new and replacement matrix macromolecules. 41
Precipitating Events Producing Cartilage Degeneration and Mechanical Failure
Osteoarthritis is a multifactorial, polygenic disorder involving mechanical, biochemical, environmental, systemic and genetic factors that contribute to imbalance between synthesis and degradation of cartilage matrix. 42,43 Chronic imbalance in matrix macromolecule turnover producing net loss of articular tissue is a required precursor to the development of osteoarthritis and joint pain.
There are numerous potential etiologic triggers that can initiate the progression of events culminating in tissue failure. For example, quadriceps muscle weakness significantly increases the risk for osteoarthritis in humans 44 and laxity in a joint may precede failure of the cartilage matrix. 45 Interstitial fluid pressurization during loading contributes more than 90% of load support, shielding the collagen-proteoglycan matrix from excessive stresses and reducing friction at the articular surfaces. 46 A chronic imbalance of shock-absorbing and weight–bearing muscles affecting joint alignment 47,48 or overloading from excessive body weight 49 induces a mild yet chronic metabolic imbalance in the affected articular cartilage.
Whenever mechanical stress exceeds the tissue’s load-bearing capacity, chondrocyte and synoviocyte secretion of the cytokines interleukin-1 b (IL-1 b ), interleukin-6 (IL-6) and tumor necrosis factor- a (TNF- a ) and nitric oxide (NO) is stimulated. These cytokines auto-stimulate chondrocyte and synoviocyte secretion of matrix metalloproteinases (collagenase, gelatinase, aggrecanase, elastase, and fibronectin-degrading stromelysin-1) and inhibit chondrocyte synthesis of cartilage-specific proteoglycans and type II collagen. The resulting imbalance between synthesis and degradation of extracellular matrix components results in a net decrease in matrix content of aggrecan, type II collagen and other matrix macromolecules. 42,43,50
IL-1 b , IL-6, TNF- a and nitric oxide also stimulate the clonal expansion of chondrocytes whose daughter cells may express a “fetal” differentiation pattern during early metabolic imbalance in articular cartilage 51 and produce inferior repair matrix prone to fibrillation and mechanical failure. 42,43 Spontaneous repair matrix produced in early asymptomatic subclinical osteoarthritic change exhibits a heterogeneous composition more closely resembling that of fibrous cartilage, 52 with inferior biomechanical competence 53,54 resulting in functional incompetence and perishability. 55 In addition, the abnormal newly-synthesized matrix may be fibronectin-deficient or may undergo accelerated hydrolysis of fibronectin by stromelysin-1, in either case disturbing chondrocyte anchorage to the extracellular matrix (“anchorage dependence”) and inducing apoptosis and hypocellularity (chondrocyte survival requires attachment to substrate). 42,43
In early asymptomatic subclinical osteoarthritic change in humans, reactive proliferation of extracellular articular cartilage matrix results in the production of abnormally large and more extensively sulfated chondroitin sulfate polymers and significantly decreased total glycosaminoglycan content (similar to the matrix of nonosteoarthritic human articular cartilage after partial enzymatic hydrolysis 56 ) and significantly decreased proportion of proteoglycans of nonosteoarthritic molecular sizes. 57-60 Overall, there is a significantly increased proportion of nonaggregated proteoglycans, significantly decreased average size of proteoglycan aggregates (aggrecan) and incorporation of significantly smaller-than-normal-for-age chondroitin sulfate chains into newly-synthesized proteoglycans, significantly decreased total chondroitin sulfate content (and therefore decreased water binding capacity), and a significantly lower ratio of chondroitin 6-sulfate to chondroitin 4-sulfate. 21,61-63 Both the abnormally small proteoglycans and the abnormally large proteoglycans are unable to aggregate with hyaluronan to form aggrecan. 64 In addition, osteoarthritic human articular cartilage exhibits increased synthesis of more readily hydrolyzable (easily degradable) collagens. 65,66
In cell culture, human articular chondrocytes harvested from osteoarthritic joint cartilage produced proteoglycans that differed from those produced by human articular chondrocytes harvested from nonosteoarthritic joint cartilage. 67 These proteoglycans resembled “fetal-type” proteoglycans with increased chondroitin 4-sulfate content and an increased percentage of smaller proteoglycans than is typical of the proteoglycans produced by chondrocytes harvested by nonosteoarthritic human articular cartilage. 68 The synthesis of temporally inappropriate proteoglycans is accompanied by a significantly accelerated rate of degradation of older, more typical-for-age proteoglycans. 69
In a rat model of the initiation of osteoarthritic change, increased mechanical stress on articular cartilage increases the ratio of chondroitin 6-sulfate to chondroitin 4-sulfate in the extracellular matrix. 70 Mechanical compression of articular cartilage stimulates intrachondrocytic cyclo-oxygenase activity, resulting in increased production of PGE 2 , an inducer of inducible NO synthase-2 (iNOS) activity; consequently, intrachondrocytic NO production is increased in proportion to the magnitude of compression and increasing local compression increases the recruitment of compression-responsive NO-producing articular chondrocytes. 71 NO stimulates chondrocytic synthesis of matrix metalloproteinases, 72 nascent (inactive) IL-1 b ,73-75 and interleukin-1-converting enzyme (ICE). 76 ICE activates nascent inactive IL-1 b . 75 Activated IL-1 b inhibits chondrocytic synthesis of proteoglycans 73,74 and collagen 73,74 and stimulates chondrocytic synthesis of stromelysin-1, 41collagenase 41 and a presumptive aggrecanase enzyme that cleaves aggrecan. 77 As osteoarthritic change progresses, IL-1 b also stimulates increased NO production; 78-81 NO further stimulates chondrocytic synthesis of matrix metalloproteinases 72 and accelerates the progression of osteoarthritis through the establishment of a cooperative positive feedback cycle. 82,83 In addition, chondrocytes harvested from osteoarthritic human articular cartilage synthesize growth-related oncogene- a (GRO- a ) in response to IL-1 b ; GRO- a stimulates degradation of fibronectin by stromelysin-1, producing anoikis (cell death resulting from loss of normal cell-substratum contact). 84
Chondrocytes harvested from osteoarthritic human joints exhibit a reduced anabolic response to insulin-like growth factor-1 (IGF-1) (“IGF resistance” 42,85 ) and may have reduced ability to transport glucose from the extracellular fluid into the cell for glycosaminoglycan synthesis. 86 Therefore, osteoarthritic chondrocytes may have an increased requirement for glucosamine of extracellular origin. 42,87-89 In addition, IGF-1 stimulates net synthesis of proteoglycans able to form aggrecan by nonosteoarthritic adult bovine articular chondrocytes in cell culture. 90 “IGF resistance” may contribute to the etiology of osteoarthritis by down-regulating the production of replacement aggrecan.
Oxidative stress also may impair the synthesis of matrix macromolecules by articular chondrocytes. Inhibition of chondrocyte γ-glutamyl-cysteine synthetase results in reduced intrachondrocytic glutathione concentration and decreased incorporation of sulfate into newly-synthesized proteoglycans and of proline into newly-synthesized collagen. 91
Chronic Degeneration of the Extracellular Matrix of Articular Cartilage is a Required Precursor to Osteoarthritis
Changes in the macromolecular composition of the extracellular matrix of articular cartilage are characteristic of clinically apparent osteoarthritis. The ratio of chondroitin 6-sulfate to chondroitin 4-sulfate in the extracellular matrix of the articular cartilage of osteoarthritic mice is significantly greater than the ratio in the extracellular matrix of articular cartilage in age-matched nonosteoarthritic mice. 92 Osteoarthritic rat articular cartilage, compared to nonosteoarthritic articular cartilage, exhibits significantly decreased total proteoglycan, chondroitin 4-sulfate and chondoitin 6-sulfate contents and significantly increased stromelysin-1 (fibronectin-degrading) activity. 93 In addition, the percentage of apoptotic chondrocytes in the tissue is significantly increased. 93 Proteoglycans in osteoarthritic adult bovine articular cartilage are larger than normal adult bovine articular cartilage proteoglycans (with larger chondroitin sulfate polymers) and closely resemble proteoglycans found in the articular cartilage matrix of calves. 33Osteoarthritic equine articular cartilage contains a significantly increased proportion of unsulfated disaccharides and a significantly decreased proportion of chondroitin 6-sulfate. 94 The articular cartilage of Cynomolgus macaque monkeys with arthritis exhibits increased production of abnormal chondroitin sulfate-containing polymers. 95
In degenerative joint disease in dogs, affected articular cartilage contains significantly increased amounts of newly-synthesized large chondroitin sulfate-rich and glucosamine- and galactosamine-poor proteoglycans typical of those produced by immature canine articular cartilage. 61,96,97 As cartilage degeneration progresses, affected canine articular cartilage exhibits significantly increased production of abnormal chondroitin sulfate-containing polymers, significantly increased water content, significantly increased proteoglycan content, significantly increased percentage of smaller proteoglycans and significantly decreased percentage of chondroitin sulfate in proteoglycans. 57,98,99 Some newly synthesized proteoglycans are abnormally large (containing abnormally long chondroitin sulfate chains) and a second population of proteoglycans are abnormally small; both have lost the ability to aggregate spontaneously with hyaluronan, compromising the hydrodynamic properties of the tissue. 100
Pathologic changes in cartilage matrix composition and organization alter the affinity of the matrix for water and produce excessive cartilage deformation under loading. 101,102 When chronic, excessive tissue deformation induces adaptive structural and compositional changes that confer increased stiffness in the tissue, 45 increasing its vulnerability to the compressive, tensile and shear forces that occur during normal joint function. 18 Grossly apparent cartilage erosion does not appear until the tissue has lost considerable stiffness and is undergoing progressive mechanical failure. 45
As a result of the changes occurring in articular cartilage, abnormally transmitted mechanical stress produces microfractures within the tissue matrix that in turn increase the stresses on surrounding tissue and induce increased chondrocyte secretion of metalloproteinases. 103 The subsequent enzymatic tissue degradation potentiates local tissue stress and initiates a positive feedback loop. Increased loading on subchondral bone stimulates the attempt to reduce mechanical stress by increasing joint surface area through the production of bone spurs (osteophytes) at the joint margins (which confer the hard bony enlargement that is characteristic of chronic osteoarthritis). 103
The Culmination of Matrix Degeneration in Osteoarthritis
In the US, the incidence of at least one joint with osteoarthritis among those aged 15 to 40 years is about 5%; this increases to over 60% among those over 65 years old. 104 Overall, the prevalence of at least mildly symptomatic 105 osteoarthritis in at least one joint is about 30%. Symptomatic osteoarthritis of the knee occurs in about 6% of US adults aged 30 years and older, 106 although radiographic changes of the femorotibial compartment occur in 5% to 15% of people aged 35 to 74 years. 107
Clinical osteoarthritis (also known as degenerative joint disease) is characterized by focal loss of cartilage and hypertrophic bone spurs. 103 Although the term osteoarthritis refers to the overgrowth of bone at the margins and subchondral areas of the joint, and despite the eventual bony involvement in later stages of the disease, osteoarthritis is marked by net loss of cartilage tissue. Initial loss of articular cartilage tissue is mild but may progress to full thickness erosions and eventual bone-to-bone contact (loss of all joint space). Narrowing of the joint space may reflect other degenerative changes in addition to articular cartilage erosion; 108 as cartilage degeneration progresses, subchondral bone density and volume increase (consistent with increased transmission of load bearing into the subchondral bone). 109
The primary complaint in osteoarthritis is pain, particularly upon use of the affected joint. 103 Pain can be accompanied by varying degrees of joint stiffness, limitation of movement, tenderness and swelling at the joint margins and loss of function. Osteoarthritis often is asymmetric. There are no systemic symptoms outside the affected joint. 103
Possible causes of pain in human osteoarthritis include osteophyte growth with stretching of the periosteum, increased intraosseous pressure, microfractures, ligament damage, capsular tension, meniscal injury and synovitis. 110Radiologically measured decrease in joint space is significantly correlated with increase in pain severity, although the clinical utility of pain assessment as an estimator of joint deterioration is under debate. 111
Bioavailability of Supplemental Glucosamine and Chondroitin Sulfates
D -Glucosamine: There are 3 forms of commercially-available D -glucosamine: D -glucosamine (MW: 179), D -glucosamine-HCl (MW: 270) and D -glucosamine sulfate (a derivative of the naturally occurring cartilage extracellular matrix constituent, aminomonosaccharide D -glucosamine; 112 MW: 456). Because of the differences in molecular size, 1500 mg of D -glucosamine-HCl provides as much D -glucosamine as is provided by 2600 mg of D -glucosamine sulfate or 1040 mg of D -glucosamine. A daily intake of 1500 mg of D -glucosamine sulfate is equivalent to a daily intake of between 15 and 30 mg/kg body weight.
In studies in rats, 90% to 95% of ingested D -glucosamine sulfate was absorbed intact into the blood and about 30% of newly absorbed D -glucosamine sulfate was incorporated into newly synthesized proteoglycans in articular cartilage tissues. 113,114 In studies in humans, consumption of 314 mg of crystalline D -glucosamine sulfate was followed by the absorption of about 280 mg (about 90%) intact into the bloodstream; about 50% of this amount (about 140 mg) survived hepatic first-pass extraction intact. 115 When the consumption of 1884 mg occurred as one bolus or in three divided intakes of 626 mg every 4 hours, there was no difference in total D -glucosamine sulfate bioavailability to systemic tissues (about 40% to 50% of the amount ingested). Other investigators have reported that over 90% of ingested D -glucosamine sulfate was absorbed intact into the human enterohepatic circulation. 116,117 One investigator reported that about 75% of ingested D -glucosamine sulfate was bioavailable to body tissues following hepatic first-pass extraction. 117
In healthy subjects, ingestion of D -glucosamine sulfate was followed by increased serum sulfate concentration. In contrast, ingestion of sodium sulfate did not effect serum sulfate concentration, suggesting that dietary supplementation with D -glucosamine sulfate might provide D -glucosamine, free sulfate and D -glucosamine sulfate for proteoglycan synthesis. 118
Chondroitin sulfates : In dogs, rats, mice and rabbits, about 0% to 15% of ingested chondroitin sulfates was absorbed intact.42,119-124 In these species, absorption favors chondroitin sulfate polymers with molecular weights <14,000 daltons. 120 In all species studied, some inorganic SO 4 -2 also was absorbed following cleavage of SO 4 -2 from the chondroitin sulfate polymers by sulfatases. 42,119-124
In humans, between 0% and 15% of an oral bolus of chondroitin sulfates is absorbed intact into the blood. 125-128 In addition, another 10% to 20% is absorbed following hydrolysis to smaller polymers (<5000 daltons) prior to absorption.128,129 However, the biological activity of these smaller polymers has been questioned. 17 The absorption of chondroitin sulfates probably is not nil; the consumption of either 800 mg or 3000 mg of mixed chondroitin sulfates significantly increased plasma chondroitin sulfate concentration 3 hours after ingestion 130,131 and the consumption of 800 mg daily for 5 days increased plasma chondroitin sulfate concentration from undetectable levels to a mean of 1.80 mcg/mL, suggesting that the systemic bioavailability of intact chondroitin sulfates in humans is about 12% of the amount ingested. 131
Biochemical and Physiologic Roles of D -Glucosamine in the Preservation of Articular Cartilage
In cultures of chondrocytes harvested from nonosteoarthritic rat articular cartilage, IL-1β inhibits the expression of UDP-glucoronosyltransferase I mRNA, resulting in decreased synthesis of proteoglycans and their precursors. 132,133Conversely, IL-1β stimulates intrachondrocytic production of the catabolism-inducing factors, NO and PGE 2 , resulting in increased expression of mRNA coding for the extracellular fibronectin degrading metalloproteinase enzyme, stromelysin-1.132 The addition of D -glucosamine to the culture medium prevented IL-1β-induced inhibition of the expression of UDP-glucuronosyltransferase I mRNA 132,133 and of proteoglycan synthesis, 132,133 as well as IL-1β-induced activation of pro-apoptotic nuclear factor K B (NF- K B). 133 The addition of D -glucosamine-HCl to the culture medium of nonosteoarthritic equine articular cartilage explants in organ culture prevented IL-1β-induced increases in the activities of stromelysin-1, collagenase and gelatinase and bacterial lipopolysaccharide (LPS)- and IL-1β-induced increases in the production of NO and PGE 2 and the degradation of extracellular matrix proteoglycans. 134-137 Similarly, crystalline D -glucosamine sulfate added to the culture media of chondrocytes harvested from osteoarthritic human articular cartilage inhibited the inherent138,139 and IL-1β-induced 132,139 catabolic activity of metalloproteases secreted by the chondrocytes and stimulated the synthesis of physiologically-relevant proteoglycans with chemical characteristics of proteoglycans synthesized by chondrocytes harvested from nonosteoarthritic human articular cartilage. 138,140 By unknown but presumably similar mechanisms, dietary supplementation with D -glucosamine sulfate (50 mg/kg body weight daily) conferred to rats resistance to kaolin-and adjuvant-induced tibio-tarsal arthritis. 141
Both D -glucosamine-HCl and D -glucosamine sulfate added to the culture medium of nonosteoarthritic rat femoral articular cartilage explants in organ culture significantly increased the rates of collagen and proteoglycan synthesis and partially prevented nonsteroidal anti-inflammatory drug- (NSAID)-induced inhibition of proteoglycan synthesis. 14 Similarly, crystalline D -glucosamine sulfate stimulated the production of proteoglycans by chondrocytes harvested from nonosteoarthritic human articular cartilage in cell culture. 142 When added to the culture media of chondrocytes harvested from osteoarthritic human articular cartilage, in which adhesion of chondrocytes to fibronectin and overall protein synthesis are significantly inhibited while extracellular collagenase activity is significantly increased, D -glucosamine restored the adhesive properties of the chondrocytes, 143 significantly reduced extracellular collagenase activity 138 and significantly increased the rate of protein synthesis. 138 Osteoarthritic articular cartilage tissue samples harvested from rabbits that had been fed diets supplemented with D -glucosamine-HCl (20 mg/kg body weight daily) exhibited significantly accelerated rates of synthesis of new proteoglycans compared to articular cartilage tissue samples harvested from unsupplemented animals. 144
D -glucosamine appears to act by interrupting message transduction. Following transport across the chondrocyte cell membrane by the GLUT-2 and GLUT-4 glucose transporters, 145,146 supplemental D -glucosamine stimulated the expression of IL-1 cell membrane receptor subtype II, which binds IL-1β with high affinity but produces an inactive receptor-ligand complex, effectively intercepting IL-1β-based signal transmission. 133 In addition, when D -glucosamine was added to the culture medium of nonosteoarthritic bovine articular cartilage explants in organ culture in concentrations that significantly inhibited IL-1β-induced aggrecanase cleavage of aggrecan, lactate production was unaffected and D -glucosamine was incorporated into newly-synthesized chondroitin sulfates. 113 D -Glucosamine-HCl also stimulated sulfate incorporation into chondroitin sulfates in the extracellular matrix of nonosteoarthritic bovine articular cartilage explants in organ culture. 147 In contrast, concentrations of D -glucosamine-HCl sufficiently high to compromise cell viability in nonosteoarthritic bovine articular cartilage explants in organ culture 148 or in nonosteoarthritic canine chondrocytes in cell culture 149 also significantly inhibited proteoglycan synthesis. These findings indicate that the inhibition of IL-1β-induced catabolism was not an artefact of D -glucosamine-induced general inhibition of chondrocyte cellular metabolism.139
In other cell culture models, D -glucosamine-HCl (0.01 to 1.0 mM) dose-dependently suppressed the superoxide anion generation induced by formyl-Met-Leu-Phe (fMLP) or complement-opsonized zymosan and inhibited the phagocytosis of complement-opsonized zymosan or IgG-opsonized latex particles. 150 Similarly, D -glucosamine-HCl significantly inhibited fMLP-induced up-regulation of CD11b, polymerization of actin, and activation via phosphorylation of pro-apoptotic p38 mitogen-activated protein kinase (MAPK). 150 In addition, D -glucosamine-HCl inhibited the release of lysozymes from phagocytozing neutrophils and suppressed neutrophil chemotaxis toward zymosan-activated serum. 150 Furthermore, supplemental D -glucosamine inhibited the activation of T-lymphocytes and the reactivity of leukocytes without producing signs of cellular toxicity. 151 All of the effects of supplemental D -glucosamine provide evidence that its immunomodulatory, anabolic and anticatabolic properties result at least in part from interaction with intercellular and intracellular cytokine-based communication systems.
Biochemical and Physiologic Roles of the Chondroitin Sulfates in the Preservation of Articular Cartilage
In cultures of chondrocytes harvested from nonosteoarthritic human knee joint articular cartilage, supplemental crystalline chondroitin sulfate polymers (Condrosulf ® , Sanova Pharma, Vienna, Austria; 55% chondroitin 4-sulfate, 38% chondroitin 6-sulfate, 5% unsulfated chondroitin sulfates, 1% disulfated chondroitin sulfates, 1% non-chondroitin compounds, average molecular weight: 24,000 daltons) bind to a specific cell membrane receptor, possibly CD36, prior to transport into the chondrocyte cell cytoplasm. 152 When added to culture media, both Condrosulf ® and a synthetic mixture of chondroitin 4-sulfate and chondroitin 6-sulfate (Structum ® , Smith Kline Corp. Philadelphia, PA; undefined polydisperse mixture of chondroitin 4-sulfate and chondroitin 6-sulfate) significantly stimulated the production of proteoglycans by nonosteoarthritic human articular cartilage chondrocytes in cell culture. 142, 153 Paradoxically, high concentrations (>1000 mcg/mL) of Condrosulf ® in the culture medium induced concentration-dependent downregulation of the expression of mRNA coding for aggrecan. 154
An undefined mix of chondroitin sulfates stimulated significant increases in the secretion of proteoglycans in nonosteoarthritic cartilage tissue 155 and by embryonic articular cartilage chondrocytes in cell culture. 156 Chondroitin 4-sulfate alone added to the culture medium stimulated significant increases in the secretion of proteoglycans and in the incorporation of sulfate into chondroitin-containing proteoglycans by embryonic articular cartilage chondrocytes in cell culture. 157
A synthetic mixture of chondroitin 4-sulfate and chondroitin 6-sulfate (Structum ® ) prevented IL-1β-induced inhibition of total proteoglycan synthesis by nonosteoarthritic human articular cartilage chondrocytes in cell culture. 153 Similarly, undefined mixtures of chondroitin sulfates (10 mcg/mL) prevented IL-1β-induced inhibition of total proteoglycan synthesis158 and IL-1β-induced stimulation of stromelysin-1 activity 153 in cultures of nonosteoarthritic human articular cartilage chondrocytes. Individually, both chondroitin 4-sulfate and chondroitin 6-sulfate significantly inhibited the secretion of the endopeptidase, cathepsin B, by cultured nonosteoarthritic rabbit articular chondrocytes. 159 However, very low concentrations of undefined mixtures of chondroitin sulfates (<1 mcg/mL) failed to significantly inhibit PGE 2 secretion or bacterial LPS-induced production of NO by nonosteoarthritic equine articular cartilage tissue explants in organ culture either alone or when added to significantly inhibitory concentrations of glucosamine-HCl. 137 In contrast, concurrent exposure of chondrocytes harvested from nonosteoarthritic articular cartilage and grown in cell culture to chondroitin sulfate (100 mcg/mL) partially inhibited the pro-apoptotic effect of NO added in amounts that when added alone significantly increased the percentage of cultures chondrocytes undergoing apoptosis. 160 In the same model system, although concurrent exposure was ineffective, the addition of chondroitin sulfate to the culture medium 72 hours before the addition of sodium nitroprusside (SNP) prevented SNP-induced stimulation of NO production and cellular apoptosis. 161
Diets supplemented with mixed chondroitin sulfates prevented chymopapain-induced degradation of knee articular cartilage in nonosteoarthritic rabbits. 162 Dietary supplementation with chondroitin 6-sulfate (100 mg/kg body weight daily) significantly inhibited the destruction of articular cartilage following subsequent injection of type II collagen in Freund’s adjuvant on day 14 in nonosteoarthritic mice 163 and significantly inhibited the depletion of proteoglycans in articular cartilage following subsequent injection of bradykinin on day 14 in nonosteoarthritic rats. 164
Fragments of large chondroitin sulfate chains similar to those found in the blood after the oral ingestion of large chondroitin sulfate chains and their degradation prior to the absorption of the fragments significantly inhibited directional chemotaxis, phagocytosis and cytokine-stimulated release of lysozymes in human leukocytes in vitro. 131 Both polydisperse mixtures of chondroitin sulfates 165,166 and Matrix ® (a defined mixture of 25% chondroitin 4-sulfate and 75% chondroitin 6-sulfate 167) inhibited the activity of human leukocyte elastase in vitro . The inhibitory activity was limited to chondroitin sulfate polymers larger in size than 2000 daltons, 168,169 may be limited to chondroitin 6-sulfate 170 and increased with the degree of sulfation of the polymers. 169,171 Although only an indirect indicator of events in cartilage, but consistent with an anticatabolic role for supplemental chondroitin sulfates, plasma elastase activity was significantly decreased in nonosteoarthritic rats following 8 days of dietary supplementation with a mixture of chondroitin sulfates (600 mg/kg body weight daily). 5 A report that in vitro both chondroitin 4-sulfate and chondroitin 6-sulfate compete with hyaluronan for digestion by hyaluronidase suggests an additional role for supplemental chondroitin sulfates in the direct protection of articular cartilage extracellular matrix macromolecules from the elevated degradative enzyme activities characteristic of asymptomatic subclinical cartilage degeneration. 172
Supplemental D -Glucosamine and Osteoarthritis
Dietary supplementation with D -glucosamine-HCl (2000 mg/day) produced a significantly greater decrease in subjective pain assessment in 12 weeks than did placebo in adults with regular knee pain that had not yet progressed to clinically identifiable osteoarthritis. 173 However, there were no significant differences in the improvement in clinical or functional tests of joint motion and balance. In contrast, dietary supplementation with D -glucosamine-HCl (1500 mg/day) for 2 months was no better than the consumption of placebo in relieving joint pain in individuals with mild to severe femorotibial osteoarthritis. 174,175
On the other hand, in 2 randomized double-blind placebo-controlled clinical studies, compared to the effects of placebo, dietary supplementation of subjects with mild to severe femorotibial osteoarthritis with crystalline D -glucosamine sulfate (Dona ® ; 1500 mg/day) for 1 month has produced significantly greater reductions in articular pain, tenderness, swelling and restriction of movement. 176,177 In another study, short-term dietary supplementation with Dona ® (1500 mg/day) 4 weeks produced a significantly greater decrease in the Lequesne functional index of impairment and a significantly greater increase in the percentage of “responders” (subjects experiencing a decrease of at least 3 points in the Lequesne index) than did placebo. 178 Compared to subjects consuming placebo, subjects consuming D -glucosamine sulfate experienced no differences in the incidence or severity of side effects or in the results of routine clinical chemistry, hematology, urinalysis, heart rate, blood pressure or body weight. Similarly, dietary supplementation with Dona ® (1500 mg/day) for 6 to 8 weeks produced significantly greater decreases in joint pain, tenderness and swelling and in the number of days until improvement was noted in joint pain, tenderness or swelling as well as significantly greater increase in the percentage of patients experiencing some degree of improvement in joint pain, tenderness or swelling without producing differences in the incidence or severity of side effects or in hematologic or urinary variables, compared to the effects of placebo consumption. 179
In long-term randomized double-blind placebo-controlled clinical studies, compared to the effects of placebo, 3 years of dietary supplementation with Dona ® (1500 mg/day) by subjects with mild to severe femorotibial osteoarthritis produced significantly greater reductions in the mean rate of femorotibial joint space narrowing (measured as the width of the medial femorotibial joint space, with the knee in full extension, by visual inspection; the “preferred, gold standard outcome” in studies of osteoarthritis 180 ), the WOMAC total pain score, the WOMAC indices of total knee health, pain, function and stiffness, the Lequesne functional index and pain assessed by a visual analog scale. 180,181 In addition, the number of subjects experiencing “severe” (i.e., > 0.5 mm) joint space narrowing was significantly smaller after 3 years of dietary supplementation with D -glucosamine sulfate. However, among those subjects consuming D -glucosamine sulfate, those with less severe osteoarthritis at baseline tended to experience better responses. Furthermore, 3 years of daily dietary supplementation with 1500 mg of D -glucosamine sulfate produced no greater number or severity of side effects, including changes in the results of routine annual clinical laboratory examinations, than did 3 years of consumption of placebo.
In a far-ranging multicenter open-label study, a total of 1208 evaluable subjects were supplemented with Dona ® (1500 mg/day) for 13 to 99 days.182 Physician ratings of subject responses were highly favorable: “good” (59% of subjects), “sufficient” (36% of subjects) and “insufficient” (5% of subjects). The best response was experienced by subjects with osteoarthritis of the knee or elbow, while those with osteoarthritis of the hip fared more poorly. The effect of D -glucosamine sulfate on pain scores was directly proportional to the duration of supplementation. In a more targeted open-label study, 69 young athletes (mean age 19 years) with cartilage degeneration of the knee (biochemically similar to osteoarthritis) received dietary supplementation with Dona ® (1500 mg/day for 4 days, then 750 mg/day for 90 to 120 additional days. 183After 120 days, complete remission of symptoms (patella-grinding sound, patella-displacement pain, patella-pressure pain) was reported for 76.5% of the subjects.
In two uncontrolled studies, subjects with femorotibial osteoarthritis were supplemented with either Dona ® (1500 mg/day) or ibuprofen (1200 mg/day) for 4 weeks. 184,185 In both studies, both groups experienced similar significant decreases in the Lequesne index of functional impairment 184 and in pain at rest, pain during movement, pain under loading and joint swelling 185 (compared to baseline). However, in both studies there were significantly more adverse events and adverse event-related trial dropouts among the subjects consuming ibuprofen. In a similar uncontrolled study, subjects with femorotibial osteoarthritis were supplemented with either Dona ® (1500 mg/day) or ibuprofen (1200 mg/day) for 8 weeks.186 In this study, Dona ® produced a significantly greater decrease in subjective assessment of knee pain with no difference in the incidence or severity of side effects.
Among subjects with osteoarthritis of the temporomandibular joint, D -glucosamine sulfate (Jamieson™; Windsor, Ontario, Canada; 1500 mg/day for 90 days) supplementation produced a significantly greater decrease in pain assessed using a visual analog scale compared to the pain relief afforded by ibuprofen (1200 mg/day for 90 days). 187 There were no significant differences between D -glucosamine sulfate and ibuprofen in the production of significant reduction in masticatory muscle pain and significant increases in pain-free mouth opening and voluntary mouth opening.
Several groups of investigators have applied the techniques of meta-analysis to evaluate dietary supplementation with D -glucosamine sulfate. One investigator concluded that the randomized double-blind placebo-controlled studies of adequate quality to include in the analysis demonstrated that dietary supplementation with D -glucosamine sulfate produced significantly greater reductions in the Lequesne Index of functional impairment, the severity of pain assessed using a visual analog scale and voluntary consumption of NSAID’s for rescue from pain than did placebo (the effect sizes were “large”).188 In addition, it was concluded that D -glucosamine sulfate has demonstrated a consistently excellent safety profile.
Other investigators concluded that dietary supplementation with D -glucosamine sulfate by individuals with osteoarthritis consistently produced significant decreases in joint pain and significant increases in joint function of small-to-moderate magnitude, 189 that dietary supplementation with D -glucosamine sulfate is “probably effective in osteoarthritis in reducing pain and in improving joint function” 107 and that dietary supplementation with D -glucosamine sulfate (1500 mg/day) produces significantly increased pain relief in individuals with femorotibial osteoarthritis accompanied by an excellent safety profile. 190
When only “high quality” studies were considered by another investigator, it was concluded that dietary supplementation with D -glucosamine sulfate by individuals with osteoarthritis produced an approxmately 50% reduction in pain with a similar improvement in function (a “large” effect consistently greater than that of placebo). 191 However, it was noted that the quality of most published studies concerning dietary supplementation with D -glucosamine sulfate by individuals with osteoarthritis has been generally poor and that the magnitude of the reported effects of dietary supplementation with D -glucosamine sulfate are likely to be inflated by weaknesses in the study designs and analysis. Nonetheless, it was concluded that, despite their poor flaws, the available published studies demonstrate a significant degree of efficacy for dietary supplementation with D -glucosamine sulfate. 191
Supplemental Chondroitin Sulfates and Osteoarthritis
In randomized, double-blind, placebo-controlled studies of subjects with femorotibial osteoarthritis ranging from mild to severe, compared to the effects of placebo, dietary supplementation with Condrosulf ® (Sanova Pharma, Vienna, Austria; 55% chondroitin 4-sulfate, 38% chondroitin 6-sulfate, 5% unsulfated chondroitin sulfates, 1% disulfated chondroitin sulfates, 1% non-chondroitin compounds, average molecular weight: 24,000 daltons; 800 mg/day for 6 months, 192 1 year193 or 2 years 194 or 1200 mg/day for 3 months 195 or 6 months 196 ) consistently produced significantly greater decreases in the Lequesne Index of functional impairment and in the severity of spontaneous joint pain assessed using a visual analog scale. After 1 year, subjects consuming 800 mg/day also exhibited significantly smaller increases in serum concentrations of osteocalcin (a biomarker of new bone formation) and keratan sulfate (a biomarker pf proteoglycan degradation) and urinary excretions of pyridinoline and deoxypyridinoline (biomarkers of collagen degradation), although overall mobility and the mean rate of narrowing of the internal femorotibial space were not affected by dietary supplementation with chondroitin sulfates. 193 However, subjects consuming 800 mg/day for 2 years exhibited significantly smaller decreases in the mean internal femorotibial space. 194 In none of these studies did dietary supplementation with chondroitin sulfates produce a significant increase in the incidence or severity of side effects. 192-196
In a randomized, double-blind, placebo-controlled study of subjects with osteoarthritis of the hip ranging from mild to severe, daily supplementation with Condrosulf ® (1200 mg for 24 weeks) produced significantly greater decreases in the Lequesne Index of functional impairment, the severity of spontaneous joint pain assessed using a visual analog scale and the voluntary use of nonsteroidal anti-inflammatory drugs (NSAID’s) for rescue from pain, although in this short-term study the mean rate of narrowing of the internal femorotibial space was not affected by dietary supplementation with chondroitin sulfates. 197 In a randomized, double-blind, placebo-controlled study of subjects with osteoarthritis of the interphalangeal joints, daily supplementation with Condrosulf ® (1200 mg for 3 years) produced a significantly greater decrease in the number of subjects whose osteoarthritis had progressed. 198 However, there was no effect on the progression of osteoarthritis of the metacarpal joints. Even after as long as 3 years of daily supplementation there were no significant differences in the incidence or severity of side effects or adverse reactions. 198
In three short-term open-label studies, dietary supplementation with Condrosulf ® (400 mg/day, 199 800 mg/day 200 or 1200mg/day 201 for 3 months) significantly reduced the severity of spontaneous joint pain assessed using a visual analog scale and the voluntary use of nonsteroidal anti-inflammatory drugs (NSAID’s) for rescue from pain in subjects with osteoarthritis of the interphalangeal, femorotibial or hip joints. One study reported 97% subject compliance with supplementation 200 and no study reported clinically significant side effects.
In a randomized, double-blind, placebo-controlled study of subjects with early mild femorotibial osteoarthritis, 2 years of dietary supplementation with Matrix ® (25% chondroitin 4-sulfate and 75% chondroitin 6-sulfate; IRBI S.p.A., Rome, Italy; 800 mg/day) produced significantly greater decreases in the severity of spontaneous joint pain assessed using a visual analog scale and the voluntary use of nonsteroidal anti-inflammatory drugs (NSAID’s) for rescue from pain. 202 In another randomized, double-blind, placebo-controlled study of subjects with early mild femorotibial osteoarthritis, 330 days of dietary supplementation with Matrix ® (200 mg/day) produced significantly greater decreases in the severity of spontaneous joint pain assessed using a visual analog scale, pain on passive movement, pain on active movement, and pain in the evening; significantly greater increases in joint mobility and ambulation; and a significantly smaller decrease in mean articular cartilage thickness (measured echographically). 203 In neither trial were the incidence or severity of side effects or adverse reactions significantly different among the subjects consuming Matrix ® or placebo. Similarly, in an open label pilot study, dietary supplementation with Matrix ® (1200 mg/day for 2 months) significantly reduced the severity of spontaneous joint pain assessed using a visual analog scale without producing side effects. 204
Subjects with femorotibial osteoarthritis ranging from mild to severe have participated in three studiess during which one group of subjects received supplemental Condrosulf ® (800 mg/day) for 3 months, placebo for 3 months, Condrosulf ® (800 mg/day) for 3 months and placebo for 3 months while a second group of subjects consumed only placebo for 12 months.205-207 In all 3 studies, after 12 months, despite having consumed only placebo for the 3 months prior, subjects previously supplemented with Condrosulf ® exhibited significantly greater decreases in the Lequesne Index of functional impairment, the severity of spontaneous joint pain assessed using a visual analog scale and the mean rate of narrowing of the internal femorotibial space. In one study, the supplemented subjects also exhibited significantly smaller decreases in femorotibial joint articular surface area, femorotibial joint space volume and femoral articular cartilage thickness. 206 In addition, between months 9 and 12 in this study (when both groups consumed placebo), unlike the subjects consuming placebo for 12 months, the subjects previously consuming Condrosulf ® did not experience rebound increase in pain. 206 In another study, after 12 months, despite having consumed only placebo for the 3 months prior, subjects previously supplemented with Condrosulf ® exhibited significantly smaller increases in the serum concentration of cartilage oligomeric matrix protein (COMP) (a biomarker of synovial and cartilage inflammation), serum concentration of keratan sulfate (a biomarker of proteoglycan degradation), and urinary excretion of pyridinoline and deoxypyridinoline (biomarkers of collagen degradation), confirming the anticatabolic properties of supplemental chondroitin sulfates. 205 In contrast, serum concentrations of osteocalcin were not significantly affected, suggesting that supplemental chondroitin sulfates do not actively influence bone metabolism or turnover. 205 In none of the 3 trials were the incidence or severity of side effects or adverse reactions significantly different among the subjects consuming Condrosulf ® or placebo. 205-207
The effectiveness of dietary supplementation with Condrosulf ® in reducing pain has been compared directly to the effectiveness of NSAID’s. Subjects with femorotibial osteoarthritis ranging from mild to severe were supplemented with either Condrosulf ® (1200 mg/day) or diclofenac sodium (150 mg/day) for 3 months, after which both groups of subjects were supplemented with placebo for another 3 months. 208 After 3 months of active supplementation, both groups of subjects exhibited similar significant decreases (compared to baseline) in the Lequesne Index of functional impairment, the severity of pain at rest assessed using a visual analog scale and the severity of pain on loading assessed using a visual analog scale. However, after 3 subsequent months of placebo, pain increased significantly in subjects previously supplemented with doclofenac sodium but did not increase in subjects previously supplemented with Condrosulf ® .
In two preliminary open-label studies, the diets of subjects with osteoarthritis of the femorotibial or hip joints were supplemented with 1000 mg/day to 1500 mg/day of Structum ® (Smith Kline Corp. Philadelphia, PA; undefined polydisperse mixture of chondroitin 4-sulfate and chondroitin 6-sulfate) for up to 4 months. 209,210 Supplementation was reported to have produced significant decreases in pain, with up to 85% of subjects reporting reduced pain and enhanced mobility. 210 When the diets of similar subjects were supplemented with 1000 mg/day of Structum ® for 6 months, pain at rest disappeared completely in 57% of subjects with femorotibial osteoarthritis and in 46% of subjects with osteoarthritis of the hip and pain with movement disappeared completely in 17% of subjects with femorotibial osteoarthritis and in 13% of subjects with osteoarthritis of the hip. 211 During the 6 months of this open-label study, joint function improved significantly while voluntary consumption of NSAID’s for rescue from pain decreased significantly. In a similar 3-month placebo-controlled study, 1000 mg/day of Structum ® produced significantly greater decreases in the Lequesne Index of functional impairment, the severity of pain at rest assessed using a visual analog scale and voluntary consumption of NSAID’s for rescue from pain. 212 After 3 subsequent months of discontinuation of supplementation, no significant return of pain occurred among the previously-supplemented subjects. There were no clinically significant side effects in any reported study of dietary supplementation with Structum ® . 209-212
In a randomized placebo-controlled study of subjects with femorotibial osteoarthritis, dietary supplementation with mixed chondroitin sulfates (1000 mg/day; unknown source) for 3 months produced significantly greater decreases in the Lequesne Index of functional impairment and the severity of pain at rest assessed using a visual analog scale. 213 No significant differences occurred in the severity of pain with activity assessed by use of a visual analog scale or in the incidence or severity of side effects. Among the previously-supplemented subjects, pain had not returned three months after discontinuation of supplementation. In a randomized placebo-controlled study of subjects with severe osteoarthritis of the proximal interphalangeal joints, dietary supplementation with mixed chondroitin sulfates (800 mg/day; unknown source) for 2 years produced significantly greater decreases in the depth of erosions of the femoral articular surface and in the number of painful joints per subject. 214
Subjects with severe osteoarthritis of the proximal interphalangeal joints received dietary supplementation with Chondral ® (a polydisperse mixture of chondroitin sulfates; Societa Prodotti Antibiotici, Milan, Italy; 800 mg/day) either with or without naproxen (500 mg/day). 215 After 2 years, the combination of Chondral ® and naproxen produced significantly slower progression of cartilage erosions, but the progression of clinical osteoarthritis was not arrested.
Several groups of investigators have applied the techniques of meta-analysis to evaluate dietary supplementation with chondroitin sulfates. One group concluded that 7 randomized double-blind placebo-controlled studies were of adequate quality to include in their analysis. 216 These studies demonstrated that when consumed at 1200 mg daily for at least 120 days, dietary supplementation with chondroitin sulfates produced significantly greater reductions in the Lequesne Index of functional impairment and in the severity of pain assessed using a visual analog scale than did placebo (the effect size was “large”). 216 In addition, 65% of subjects consuming chondroitin sulfates will be expected to benefit more than if they were consuming placebo and, in general, adverse effects were more frequent when placebo was consumed than when chondroitin sulfates were consumed. 216 Other investigators concluded that dietary supplementation with chondroitin sulfates by individuals with osteoarthritis consistently produced significant decreases in joint pain and significant increases in joint function of small-to-moderate magnitude 189 and that dietary supplementation with chondroitin sulfates is “probably effective in osteoarthritis in reducing pain and in improving joint function.” 107
When only “high quality” studies were considered by another investigator, it was concluded that dietary supplementation with chondroitin sulfates by individuals with osteoarthritis produced an approximately 50% reduction in pain with a similar improvement in function (a “large” effect consistently greater than that of placebo). 191 However, it was noted that the quality of most published studies concerning dietary supplementation with chondroitin sulfates by individuals with osteoarthritis has been generally poor and that the magnitude of the reported effects of dietary supplementation with chondroitin sulfates are likely to be inflated by weaknesses in the study designs and analysis. Nonetheless, it was concluded that, despite their flaws, the available published studies demonstrate a significant degree of efficacy for dietary supplementation with chondroitin sulfates. 191
The application of a pharmacokinetic-pharmacodynamic model of intake-dependent effects resulted in the estimation that dietary supplementation with chondroitin sulfates (especially Condrosulf ® , 1200 mg/day) “can reduce baseline pain and algofunctional indices by over 80%”; it was estimated that about half of this benefit can be experienced in about 35 days of supplementation. 217
Comparison of Supplemental D -Glucosamine and the Chondroitin Sulfates
In an open-label trial, subjects with femorotibial osteoarthritis consumed either D -glucosamine sulfate (unknown source; 1500 mg/day) or mixed chondroitin sulfates (unknown source; 675 mg/day). 218 After 3 months there were no significant differences between the two groups of subjects; 72% of all subjects self-assessed their improvement as “good” without side effects. The extent of improvement in pain during moderate exercise following supplementation was inversely proportional to the severity of pain during moderate exercise prior to the initiation of supplementation (subjects with the most severe pain responded the least to either dietary supplement).
Combination of Chondroitin Sulfates and D -Glucosamine in an Animal Model of Osteoarthritis
In a rabbit surgical model of osteoarthritis, following surgery five groups of rabbits were fed either a control diet or the control diet supplemented with either D -glucosamine HCl, mixed chondroitin sulfates, manganese ascorbate or Cosamin ® for 16 weeks. 219 Upon sacrifice, the rabbits fed either the control diet or the control diet supplemented with either D -glucosamine HCl, mixed chondroitin sulfates, or manganese ascorbate exhibited no significant differences in the area of articular cartilage surface lesions, the percentage of animals exhibiting severe lesions, the rates of synthesis or degradation of articular cartilage proteoglycans or the magnitude of IL-1β-induced collagenase activity. In contrast, dietary supplementation with Cosamin ® produced significantly greater decreases in the area of articular cartilage surface lesions, the percentage of animals exhibiting severe lesions and the magnitude of IL-1β-induced collagenase activity. In this model, Cosamin ® had no effect on the rates of synthesis or degradation of articular cartilage proteoglycans.
Combinations of Chondroitin Sulfates and D -Glucosamine and Osteoarthritis
In a randomized double-blind placebo-controlled clinical trial, subjects with mild to moderate femorotibial osetoarthritis supplemented their diets with either a combination of D -glucosamine-HCl (1000 mg/day), mixed chondroitin sulfates (800 mg/day) and manganese ascorbate (152 mg/day) (2 tablets of Cosamin ® ; Nutramax Laboratories, Inc.) or placebo. 220After 6 months, dietary supplementation with Cosamin ® was associated with significantly greater decreases in the Lequesne index of functional impairment, although there was no difference in WOMAC pain scores or in subject self-assessment between subjects supplemented with Cosamin ® and those supplemented with placebo. In addition, subjects with severe femorotibial osetoarthritis experienced little improvement. There also was no difference in the incidence or severity of side effects. In another randomized double-blind placebo-controlled clinical trial, subjects with mild to moderate femorotibial osetoarthritis or osteoarthritis of the lower back supplemented their diets with either a combination of D -glucosamine-HCl (1500 mg/day), mixed chondroitin sulfates (1200 mg/day) and manganese ascorbate (228 mg/day) (3 tablets of Cosamin ® ; Nutramax Laboratories, Inc.) or placebo. 221 After 16 weeks, Cosamin ® -supplemented subjects with femorotibial osetoarthritis exhibited significantly greater decreases in summary disease score, subject self-assessment of pain, severity of pain assessed using a visual analog scale, but there was no difference in maximum running times. Subjects with osteoarthritis of the lower back exhibited no response to the dietary supplement. There were no intergroup differences in the incidence or severity of side effects.
In a randomized double-blind placebo-controlled trial, dietary supplementation with D -glucosamine-HCl (1500 mg/day) plus mixed chondroitin sulfates (1200 mg/day) was compared with placebo in subjects with painful osteoarthritis of the temporomandibular joint. 222 After 12 weeks, subjects supplemented with D -glucosamine-HCl plus mixed chondroitin sulfates exhibited significantly greater decreases in temporomandibular joint tenderness and sounds and in voluntary consumption of pain relieving medications without the production of side effects. In an uncontrolled study of subjects with chronic temporomandibular joint osteoarthritis, 80% of subjects reported self-perceived decreases in temporomandibular joint sounds during dietary supplementation with a combination of D -glucosamine-HCl (1600 mg/day), mixed chondroitin 4- and 6-sulfates (1200 mg/day) and calcium ascorbate (1000 mg/day) (NOW Foods, Glendale Heights, IL). 223
Daily Intake of Supplemental Glucosamine that is Effective in Reducing the Risk of Osteoarthritis
The reliable and credible scientific literature indicates that daily dietary supplementation with 1500 mg of D -glucosamine sulfate is effective in reducing the risk of osteoarthritis.
When combined with dietary supplementation with chondroitin sulfates (at least 800 mg/day), daily dietary supplementation with 1000 mg of D -glucosamine-HCl is effective in reducing the risk of osteoarthritis.
Daily Intake of Supplemental Chondroitin Sulfates that is Effective in Reducing the Risk of Osteoarthritis
The reliable and credible scientific literature indicates that daily dietary supplementation with 1200 mg of chondroitin sulfates (containing chondroitin 4-sulfate and chondroitin 6-sulfate in approximately equal proportions), whether consumed alone or in combination with supplemental D -glucosamine sulfate or D -glucosamine-HCl is effective in reducing the risk of osteoarthritis.
Safety of Daily Intakes of Supplemental Chondroitin Sulfates and D-Glucosamine that are Effective in Reducing the Risk of Osteoarthritis
D -Glucosamine is present in all foods containing cartilage or glycoproteins. 17 It has not been possible to estimate an LD50 for oral D -glucosamine sulfate because no deaths have occurred in mice and rats from intakes of up to 5000 mg/kg body weight. 224 Daily dietary supplementation with 2149 mg of D -glucosamine sulfate per kg body weight produced no systemic or gastrointestinal adverse reactions in dogs. 141 Horses fed 8 g of D -glucosamine-HCl daily for 48 weeks (equivalent to about 16 mg/kg body weight daily in an adult human) exhibited no effects on bone metabolism. 225 In humans, intra-articular (200 mg) 226 or intramuscular injection of D -glucosamine sulfate (200 mg once 226 or 400 mg daily for 7 days 227,228 ) produced no adverse reactions. Dietary supplementation with D -glucosamine sulfate 176-181 or D -glucosamine-HCl 173-175,220-222 for up to 3 years did not produce an increase in the incidence or severity of side effects in placebo-controlled human studies.
The most common side effects reported by humans consuming D -glucosamine sulfate include reversible epigastric pain, epigastric tenderness, heartburn, nausea, diarrhea, dyspepsia, vomiting, constipation, drowsiness, headaches, and mild skin reactions. 182,185 Oral D -glucosamine sulfate does not interfere with the efficacy of medications for cardiovascular, liver, or lung diseases, diabetes or depression 227 or produce insulin resistance in rats 229 or humans. 181,230 However, oral D -glucosamine sulfate may potentiate active peptic ulcers. 182 Obesity may reduce responsiveness to dietary supplementation with D -glucosamine sulfate. 182
In rats and rabbits, oral chondroitin sulfate polymers (1 g/kg body weight daily) produced no effects on mutagenesis or reproductive function. 5 In the isolated rabbit intestinal loop model of the digestive tract, no change in the amplitude of intestinal contractions or in the tonicity of the intestine was noted in the presence of 1 to 3 mg/mL chondroitin sulfate polymers. At intakes of 0.25 to 1.0 g/kg body weight, no change occurred in the rate of intestinal transit in mice. Chondroitin sulfate polymers do not modify the coagulation time. Intravenous chondroitin sulfate polymers (25 to 100 mg/kg body weight, perfused at a rate of 25 mg/min) had no effect on the human electrocardiogram; 100 mg/kg induced a slight and transitory decrease of arterial pressure. However, chondroitin sulfate polymers can cause an increased respiratory rate and amplitude. No change in the volume or the electrolyte concentration of human urine was found after subcutaneous administration of 100 mg/mL of chondroitin sulfate polymers. 5
In an analysis of 16 human studies that included a total of 372 subjects, it was concluded that dietary supplementation with chondroitin sulfate polymers (800 mg/day) did not produce more adverse events than did placebo. 231 Dietary supplementation with chondroitin sulfate polymers for up to 2 years did not increase the incidence or severity of side effects in placebo-controlled human studies. 192-198,202,203,205-207,212-214,220-222
• Maintaining the structural and functional integrity of the proteoglycan component of the extracellular matrix of articular cartilage is required for preservation of healthy joint architecture and biomechanics.
• Imbalanced metabolism favoring catabolism within the extracellular matrix of articular cartilage produces degenerative changes in the proteoglycan composition of the matrix.
• Compromise of the structural and functional integrity of the proteoglycan component of the extracellular matrix of articular cartilage results in net loss of articular cartilage tissue, inferior biomechanical competence and structural deformation of joint architecture.
• Net degradation of the extracellular matrix of articular cartilage, accompanied by the production of spontaneous repair matrix with abnormal proteoglycan composition, results in asymptomatic subclinical osteoarthritic change.
• The progression of asymptomatic osteoarthritic change to osteoarthritis is not inevitable.
• The progression of osteoarthritic change is required in order for abnormalities in articular cartilage composition and structure to progress to osteoarthritis.
• Osteoarthritic change in the absence of joint pain represents a modifiable risk factor for later development of osteoarthritis.
• Dietary supplementation with D -glucosamine, glucosamine-HCl, glucosamine sulfate or chondroitin sulfates contributes to the preservation of articular cartilage, inhibits the initiation of osteoarthritic change in articular cartilage and inhibits the progression of osteoarthritic change to symptomatic osteoarthritis.
• Dietary supplementation with D -glucosamine, glucosamine-HCl, glucosamine sulfate or chondroitin sulfates is an effective modifier of osteoarthritic change and reduces the risk for osteoarthritis.
In conclusion, I find that there is significant scientific agreement in support of the following health claims:
Glucosamine may reduce the risk of osteoarthritis.
Chondroitin sulfate may reduce the risk of osteoarthritis.
Glucosamine and chondroitin sulfate may reduce the risk of osteoarthritis.
Glucosamine may reduce the risk of osteoarthritis-related joint pain, tenderness and swelling.
Chondroitin sulfate may reduce the risk of osteoarthritis-related joint pain, tenderness and swelling.
Glucosamine and chondroitin sulfate may reduce the risk of osteoarthritis-related joint pain, tenderness and swelling.
Glucosamine may reduce the risk of joint degeneration.
Chondroitin sulfate may reduce the risk of joint degeneration.
Glucosamine and chondroitin sulfate may reduce the risk of joint degeneration,
Glucosamine may reduce the risk of cartilage deterioration.
Chondroitin sulfate may reduce the risk of cartilage deterioration.
Glucosamine and chondroitin sulfate may reduce the risk of cartilage deterioration.
Michael J. Glade, Ph.D., F.A.C.N., C.N.S.
(a copy of my CV is attached)
1. Sandy JD, Plaas AHK. Age-related changes in the kinetics of release of proteoglycans from normal rabbit cartilage explants. J Orthop Res 1986;4:263-272.
2. Ilic MZ, Haynes SR, Winter GM, Handley CJ. Kinetics of release of aggrecan from explant cultures of bovine cartilage from different sources and from animals of different ages. Acta Orthop Scand Suppl 1995;266:33-37.
3. Barclay TS, Tsourounis C, McCart GM. Glucosamine. Ann Pharmacother 1998;32:574-579.
4. McDevitt CA. Biochemistry of articular cartilage. Nature of proteoglycans and collagen of articular cartilage and their role in ageing and in osteoarthrosis. Ann Rheum Dis 1973;32:364-378.
5. Bali J-P, Cousse H, Neuzil E. Biochemical basis of the pharmacologic action of chondroitin sulfates on the osteoarticular system. Semin Arthritis Rheum 2001;31:58-68.
6. Rokosová-Čmuchalová B, Bentley JP. Relation of collagen synthesis to chondroitin sulfate synthesis in cartilage. Biochem Pharmacol 1968;Suppl:315-328.
7. Rodén L, Baker JR, Helting T, Schwartz NB, Stoolmiller AC, Yamagata S, Yamagata T. Biosynthesis of chondroitin sulfate. In: Pigman WW, Wolfrom ML (eds.). Advances in Carbohydrate Chemistry. Volume 2 . Academic Press, New York , 1946, pp. 638-676.
8. Telser A, Robinson HC, Dorfman A. The biosynthesis of chondroitin sulfate. Arch Biochem Biophys 1966;116:458-465.
9. Stacey M. The chemistry of mucopolysaccharides and mucoproteins. In: Pigman WW, Wolfrom ML (eds.). Advances in Carbohydrate Chemistry. Volume 2 . Academic Press, New York , 1946, pp. 161-201.
10. Telser A, Robinson HC, Dorfman A. The biosynthesis of chondroitin-sulfate protein complex. Proc Natl Acad Sci USA 1965;54:912-919.
11. Brand HS, van Kampen GP, van de Stadt RJ, Kuijer R, van der Korst JK. Effect of sulfate concentration on glycosaminoglycan synthesis in explant cultures of bovine articular cartilage. Cell Biol Int Rep 1989;13:153-162.
12. Deal CL, Moskowitz RW. Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin North Am 1999;25:379-395.
13. Karzel K, Domenjoz R. Effects of hexosamine derivatives and urinic acid derivatives on glycosaminoglycane metabolism of fibroblast cultures. Pharmacology 1971;5:337-345.
14. Vidal y Plana RR, Bizzarri D, Rovati AL. Articular cartilage pharmacology: I. In vitro studies on glucosamine and non steroidal antiinflammatory drugs. Pharmacol Res Commun 1978;10:557-569.
15. Arrambide E, Patrone MG, Calcagno M. Inhibition by 5′-adenylate of glucosamine 6-phosphate formation in chick cartilage. Experientia 1968;24:896.
16. de los Reyes GC, Koda RT, Lien EJ. Glucosamine and chondroitin sulfates in the treatment of osteoarthritis: A survey. Prog Drug Res 2000;55:81-103.
17. Bucci LR. Glycosaminoglycans. In: Bucci LR. Nutrition Applied to Injury Rehabilitation and Sports Medicine . CRC Press, Boca Raton , FL , 1995, pp. 177-265.
18. Brief AA, Maurer SG, Di Cesare PE. Use of glucosamine and chondroitin sulfate in the management of osteoarthritis. J Am Acad Orthop Surg 2001;9:71-78.
19. Bayliss MT, Osborne D, Woodhouse S, Davidson C. Sulfation of chondroitin sulphate in human articular cartilage. The effect of age, topographical position, and zone of cartilage on tissue composition. J Biol Chem 1999;274:15892-15900.
20. Sato S, Rahemtulla F, Prince CW, Tomana M, Butler WT. Proteoglycans of adult bovine compact bone. Connect Tissue Res 1985;14:65-75.
21. Burkhardt D, Michel BA, Baici A, Kissling R, Theiler R. Comparison of chondroitin sulphate composition of femoral head articular cartilage from patients with femoral neck fractures and osteoarthritis and controls. Rheumatol Int 1995;14:235-241.
22. Hardingham TE, Fosang AJ, Dudhia J. The structure, function and turnover of aggrecan, the large aggregating proteoglycan from cartilage. Eur J Clin Chem Clin Biochem 1994;32:249-257.
23. Knudson CB, Knudson W. Cartilage proteoglycans. Semin Cell Dev Biol 2001;12:69-78.
24. Hardingham T. Changes in chondroitin sulphate structure induced by joint disease. Acta Orthop Scand 1995;66(Suppl 266):107-110.
25. Caplan AJ. Cartilage. Sci Amer 1984;251:82-90.
26. Hassel JR, Kimura JH, Hascal VC. Proteoglycan core protein families. Annu Rev Biochem 1985;55:539-567.
27. Hardingham T. Chondroitin sulfate and joint disease. Osteoarthritis Cartilage 1998;6(Suppl A):3-5.
28. Muir H, Maroudas A, Wingham J. The correlation of fixed negative charge with glycosaminoglycan content of human articular cartilage. Biochim Biophys Acta 1969;177:494.
29. Kempson GE, Muir H, Swanson SV, Freeman MA. Correlations between the compressive stiffness and chemical constituents of human articular cartilage. Biochim Biophys Acta 1970;215:70-77.
30. Mankin HJ, Thrasher AZ. The effect of age on glycosaminoglycan synthesis in rabbit articular and costal cartilages. J Rheumatol 1977;4:343-350.
31. Murota S-I, Honda A, Abe M, Mori Y. Mechanism of age-dependent decrease in sulfation of chondroitin sulfate. Adv Exp Med Biol 1980;129:39-46.
32. Cole TC, Ghosh P, Taylor TK. Variations of the proteoglycans of the canine intervertebral disc with ageing. Biochim Biophys Acta 1986;880:209-219.
33. Axelsson I, Bjelle A. Proteoglycan structure of bovine articular cartilage. Variation with age and in osteoarthrosis. Scand J Rheumatol 1979;8:217-221.
34. Front P, Aprile F, Mitrovic DR , Swann DA. Age-related changes in the synthesis of matrix macromolecules by bovine articular cartilage. Connect Tissue Res 1989;19:121-133.
35. Bihari-Varga M, Biro T. Thermoanalytical investigations on the age-related changes in articular cartilage, meniscus and tendon. Gerontologia 1971;17:2-15.
36. Choi HU, Meyer K. The structure of keratan sulphates from various sources. Biochem J 1975;151:543-553.
37. Hjertquist SO, Lemperg R. Identification and concentration of the glycosaminoglycans of human articular cartilage in relation to age and osteoarthritis. Calcif Tissue Res 1972;10:223-237.
38. Meachim G. Age changes in articular cartilage. Clin Orthop 1969;64:33-44.
39. Adams P, Muir H. Qualitative changes with age of proteoglycans of human lumbar discs. Ann Rheum Dis 1976;35:289-296.
40. Perricone E, Palmoski MJ, Brandt KD. Failure of proteoglycans to form aggregates in morphologically normal aged human hip cartilage. Arthritis Rheum 1977;20:1372-1380.
41. Dozin B, Malpeli M, Camardella L, Cancedda R, Pietrangelo A. Response of young, aged and osteoarthritic human articular chondrocytes to inflammatory cytokines: Molecular and cellular aspects. Matrix Biol 2002;21:449-459.
42. Mobasheri A, Vannucci SJ, Bondy CA, Carter SD, Innes JF, Arteaga MF, Trujillo E, Ferraz I, Shakibaei M, Martin-Vasallo P. Glucose transport and metabolism in chondrocytes: A key to understanding chondrogenesis, skeletal development and cartilage degradation in osteoarthritis. Histol Histopathol 2002;17:1239-67.
43. Aigner T, Kim HA. Apoptosis and cellular vitality. Issues in osteoarthritic cartilage degeneration. Arthritis Rheum 2002;46:1986-1996.
44. Slemenda C, Brandt KD, Heilman DK, Mazzuca S, Braunstein EM, Katz BP, Wolinsky FD. Quadriceps weakness and osteoarthritis of the knee. Ann Intern Med 1997;127:97-104.
45. Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, Kington RS, Lane NE, Nevitt MC, Zhang Y, Sowers M, McAlindon T, Spector TD, Poole AR, Yanovski SZ, Ateshian G, Sharma L, Buckwalter JA, Brandt KD, Fries JF. Osteoarthritis: New insights. Part I: The disease and its risk factors. Ann Intern Med 2000;133:635-646.
46. Soltz MA, Ateshian GA. Experimental verification and theoretical prediction of cartilage interstitial fluid pressurization at an impermeable contact interface in confined compression. J Biomech 1998;31:927-934.
47. Sharma L, Song J, Felson DT, Cahue S, Shamiyeh E, Dunlop DD . The role of knee alignment in disease progression and functional decline in knee osteoarthritis . JAMA 2001;286:188-195.
48. Hurley MV. The role of muscle weakness in the pathogenesis of osteoarthritis. Rheum Dis Clin North Am 1999;25:283-298.
49. Cicuttini FM, Wluka AE, Wang Y, Stuckey SL, Davis SR. Effect of estrogen replacement therapy on patella cartilage in healthy women. Clin Exp Rheumatol 2003;21:79-82.
50. Saamanen A-M, Tammi M, Kiviranta I, Jurvelin J, Helminen HJ. Maturation of proteoglycan matrix in articular cartilage under increased and decreased joint loading. A study in young rabbits. Connect Tissue Res 1987;16:163-175.
51. Girkontaite I, Frischholz S, Lammi P, Wagner K, Swoboda B, Aigner T, Von der Mark K . Immunolocalization of type X collagen in normal fetal and adult osteoarthritic cartilage with monoclonal antibodies. Matrix Biol 1996;15:231-238.
52. Furukawa T, Eyre DR , Koide S, Glimcher MJ. Biochemical studies on repair cartilage resurfacing experimental defects in the rabbit knee. J Bone Joint Surg 1980;62A:79-89.
53. Heath CA, Magari SR. Mini-review: Mechanical factors affecting cartilage regeneration in-vitro. Biotechnol Bioeng 1996;50:430-437.
54. Ahsan T, Lottman LM, Harwood F, Amiel D, Sah RL. Integrative cartilage repair: Inhibition by beta-aminopropionitrile. J Orthop Res 1999;17:850-857.
55. Hunziker EB. Articular cartilage repair: Basic science and clinical progress. A review of the current status and prospects. Osteoarthritis Cartilage 2001;10:432-463.
56. Barland P, Janis R, Sandson J. Immunofluorescent studies of human articular cartilage. Ann Rheum Dis 1966;25:156-164.
57. Caterson B, Mahmoodian F, Sorrell JM, Hardingham TE, Bayliss MT, Carney SL, Ratcliffe A, Muir H. Modulation of native chondroitin sulphate structure in tissue development and in disease. J Cell Sci 1990;97:411-417.
58. Axelsson S, Holmlund A, Hjerpe A. Glycosaminoglycans in normal and osteoarthrotic human temporomandibular joint disks. Acta Odontol Scand 1992;50:113-119.
59. Plaas AH, West LA , Wong-Palms S, Nelson FR. Glycosaminoglycan sulfation in human osteoarthritis. Disease-related alterations at the non-reducing termini of chondroitin and dermatan sulfate. J Biol Chem 1998;273:12642-12649.
60. Caterson B, Hughes CE, Roughley P, Mort JS. Anabolic and catabolic markers of proteoglycan metabolism in osteoarthritis. Acta Orthop Scand Suppl 1995;266:121-124.
61. Adams ME. Changes in aggrecan populations in experimental osteoarthritis. Osteoarthritis Cartilage 1994;2:155-164.
62. Brandt KD, Palmoski M. Organization of ground substance proteoglycans in normal and osteoarthritic knee cartilage. Arthritis Rheum 1976;19:209-215.
63. Hjertquist SO, Wasteson A. The molecular weight of chondroitin sulphate from human articular cartilage. Effect of age and of osteoarthritis. Calcif Tissue Res 1972; 10:31 -37.
64. Mitrovic DR . Synthesis of abnormal articular cartilage proteoglycans in rapidly destructive arthropathy (osteoarthritis). Rheumatol Int 1991; 11:55 -61.
65. Adam M, Musilova J, Deyl Z. Cartilage collagen in osteoarthrosis. Clinica Chim Acta 1976;69:53-59 .
66. Nimni M, Deshmukh K. Differences in collagen metabolism between normal and osteoarthritic human articular cartilage. Science 1973;181:751-752.
67. Malemud CJ, Papay RS, Hering TM, Holderbaum D, Goldberg VM, Haqqi TM. Phenotypic modulation of newly synthesized proteoglycans in human cartilage and chondrocytes. Osteoarthritis Cartilage 1995;3:227-238.
68. Danao-Camara T. Potential side effects of treatment with glucosamine and chondroitin (letter). Arthritis Rheum 2000;43(:2853.
69. Carroll G, McCappin S, Bell M, Schwarzer A, Breidahl P. Comparison of keratan sulphate concentrations and the size distribution of proteoglycans in the synovial fluid of patients with osteoarthritis and pyrophosphate arthropathy. Rheumatol Int 1991;11:63-68.
70. Carvalho RS, Yen EH, Suga DM. Glycosaminoglycan synthesis in the rat articular disk in response to mechanical stress. Am J Orthod Dentofacial Orthop 1995;107:401-410 .
71. Fermor B, Weinberg JB, Pisetsky DS, Misukonis MA, Fink C, Guilak F. Induction of cyclooxygenase-2 by mechanical stress through a nitric oxide-regulated pathway. Osteoarthritis Cartilage 2002;10:792-798 .
72. Murrell GAC, Jang D, Williams RJ. Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 1995;206:15-21 .
73. Järvinen TAH, Moilanen T, Järvinen TLN, Moilanen E. Nitric oxide mediates interleukin-1 induced inhibition of glycosaminoglycan synthesis in rat articular cartilage. Mediators Inflamm 1995;4:107-111 .
74. Taskiran D, Stefanovic-Racic M, Georgescu HI, Evans CH. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem Biophys Res Commun 1994;200:142-148 .
75. Saha N, Moldovan F, Tardiff G, Pelletier J-P, Cloutier J-M, Martel-Pelletier J. Interleukin-1β-converting enzyme/caspase-1 in human osteoarthritic tissues: Localization and role in the maturation of interleukin-1β and interleukin-18. Arthritis Rheum 1999;42:1577-1587 .
76. Boileau C, Martel-Pelletier J, Moldovan F, Jouzeau JY, Netter P, Manning PT, Pelletier JP. The in situ up-regulation of chondrocyte interleukin-1-converting enzyme and interleukin-18 levels in experimental osteoarthritis is mediated by nitric oxide. Arthritis Rheum 2002;46(:2637-2647.
77. Lark MW, Gordy JT, Weidner JR, Ayala J, Kimura JH, Williams HR, Mumford RA, Flannery CR, Carlson SS, Iwata M, Sandy JD. Cell-mediated catabolism of aggrecan. Evidence that cleavage at the “aggrecanase” site (Glu 373 -Ala 374 ) is a primary event in proteolysis of the interglobular domain. J Biol Chem 1995;270:2550-2556.
78. Amin AR, Abramson SB. The role of nitric oxide in articular cartilage breakdown in osteoarthritis. Curr Opin Rheumatol 1998;10:263-268.
79. Studer R, Jaffurs D, Stefanovic-Racic M, Robbins PD, Evans CH. Nitric oxide ion osteoarthritis. Osteoarthritis Cartilage 1999;7:377-379.
80. Lotz M. The role of nitric oxide in articular cartilage damage. Rheum Dis Clin North Am 1999;25:269-282.
81. Amin AR, Di Cesare PE, Vyas P, Attur MG, Tzeng E, Billiar TR, Stuchin SA, Abramson SB. The expression and regulation of nitric oxide synthase in human osteoarthritis-affected chondrocytes: Evidence for an inducible “neuronal-like” nitric oxide synthase. J Exp Med 1995;182:2097-2102 .
82. Pelletier JP, Jovanovic D, Fernandes JC, Manning P, Connor JR, Currie MG, Di Battista JA, Martel-Pelletier J. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum 1998;41:1275-1286.
83. Pelletier JP, Jovanovic DV, Lascau-Coman V, Fernandes JC, Manning PT, Connor JR, Currie MG, Martel-Pelletier J. Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: Possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis Rheum 2000;43:1290-1299.
84. Borzi RM, Mazzetti I, Magagnoli G, Paoletti S, Uguccioni M, Gatti R, Orlandini G, Cattini L, Facchini A. Growth-related oncogene alpha induction of apoptosis in osteoarthritis chondrocytes. Arthritis Rheum 2002;46(:3201-3211 .
85. Cai L, Okumu FW, Cleland JL, Beresini M, Hogue D, Lin Z, Filvaroff EH. A slow release formulation of insulin as a treatment for osteoarthritis. Osteoarthritis Cartilag e 2002;10:692-706 .
86. Doré S, Pelletier JB, DiBattista JA, Tardiff G, Brazeau P, Martel-Pelletier J. Human osteoarthritic chondrocytes possess an increased number of insulin-like growth factor-1 binding sites but are unresponsive to its stimulation. Possible role of IGF-1 binding proteins. Arthritis Rheum 1994;37:253-263.
87. Kim JJ, Conrad HE. Kinetics of mucopolysaccharide and glycoprotein synthesis by chick embryo chondrocytes. Effect of D -glucose concentration in the culture medium. J Biol Chem 1976;251:6210-6217.
88. Sweeney C, Mackintosh D, Mason RM. UDP-sugar metabolism in Swarm rat chondrosarcoma chondrocytes. Biochem J 1993;290:563-570.
89. Rosenbloom AL, Silverstein JH. Connective tissue and joint disease in diabetes mellitus. Endocrinol Metab Clin Nort Am 1996;25:473-483 .
90. Chopra R, Anastassiades T. Specificity and synergism of polypeptide growth factors in stimulating the synthesis of proteoglycans and a novel high molecular weight anionic glycoprotein by articular chondrocyte cultures. J Rheumatol 1998;25:1578-1584.
91. Habuchi O, Miyachi T, Kaigawa S, Nakashima S, Fujiwara C, Hisada M. Effects of glutathione depletion on the synthesis of proteoglycan and collagen in cultured chondrocytes. Biochim Biophys Acta 19911093:153-161 .
92. Gaffen JD, Gleave SJ, Crossman MV, Bayliss MT , Mason RM. Articular cartilage proteoglycans in osteoarthritic STR/Ort mice. Osteoarthritis Cartilage 1995;3:95-104 .
93. Lozoya KAA, Flores JB. A novel rat osteoarthrosis model to assess apoptosis and matrix degradation. Pathol Res Pract 2000;196:729-745 .
94. Brown MP, West LA, Merritt KA, Plaas AH. Changes in sulfation patterns of chondroitin sulfate in equine articular cartilage and synovial fluid in response to aging and osteoarthritis. Am J Vet Res 1998;59:786-791.
95. Carlson CS, Loeser RF, Johnstone B, Tulli HM, Dobson DB, Caterson B. Osteoarthritis in cynomolgus macaques. II. Detection of modulated proteoglycan epitopes in cartilage and synovial fluid. J Orthop Res 1995;13:399-409.
96. Adams ME. Target tissue models: Cartilage changes in experimental osteoarthritis in the dog. J Rheumatol Suppl 1983;11:111-113.
97. Adams ME, Grant MD, Ho A. Cartilage proteoglycan changes in experimental canine osteoarthritis. J Rheumatol 1987;Spec No:107-109.
98. Inerot S, Heinegard D, Audell L, Olsson SE. Articular-cartilage proteoglycans in aging and osteoarthritis. Biochem J 1978;169:143-156.
99. Carney SL, Billingham ME, Caterson B, Ratcliffe A, Bayliss MT, Hardingham TE, Muir H. Changes in proteoglycan turnover in experimental canine osteoarthritic cartilage. Matrix 1992;12:137-147 .
100. Carney SL, Billingham ME, Muir H, Sandy JD. Structure of newly synthesised ( 35 S)-proteoglycans and ( 35 S)-proteoglycan turnover products of cartilage explant cultures from dogs with experimental osteoarthritis. J Orthop Res 1985;3:140-147.
101. Akizuki S, Mow VC, Muller F, Pita JC, Howell DS. Tensile properties of human knee joint cartilage. II. Correlations between weight bearing and tissue pathology and the kinetics of swelling . J Orthop Res 1987;5:173-186.
102. Armstrong CG, Mow VC. Variations in the intrinsic mechanical properties of human articular cartilage with age, degeneration, and water content. J Bone Joint Surg [Am] 1982;64:88-94.
103. Dieppe P. Osteoarthritis. Time to shift the paradigm. Br Med J 1999;318:1229-1230.
104. Buckwalter JA, Stanish WD, Rosier RN, Schenck RC Jr, Dennis DA, Coutts RD. The increasing need for nonoperative treatment of patients with osteoarthritis. Clin Orthop Rel Res 2001;385:36-45.
105. Mili F, Helmick CG, Zack MM. Prevalence of arthritis: analysis of data from the US Behavioral Risk Factor Surveillance System, 1996-99. J Rheumatol 2002;29:1981-1988.
106. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998;41:1343-1355.
107. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JWJ, Cluzeau F, Cooper C, Dieppe PA, Günther K-P, Häuselmann HJ, Herrero-Beaumont G, Kaklamanis PM, Leeb B, Lequesne M, Lohmander S, Mazieres B, Mola E-M, Pavelka K, Serni U, Swoboda B, Verbruggen AA, Weseloh G, Zimmermann-Gorska I. EULAR recommendations for the management of knee osteroarthritis: Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000;59:936-944.
108. Adams JG, McAlindon T, Dimasi M, Carey J, Eustace S. Contribution of meniscal extrusion and cartilage loss to joint space narrowing in osteoarthritis. Clin Radiol 1999;54:502-506.
109. Bobinac D, Spanjol J, Zoricic S, Maric I. Changes in articular cartilage and subchondral bone histomorphometry in osteoarthritic knee joints in humans. Bone 2003;32:284-290.
110. Creamer P. Osteoarthritis pain and its treatment. Curr Opinion Rheumatol 2000;12:450-455.
111. Bruyere O, Honore A, Rovati LC, Giacovelli G, Henrotin YE, Seidel L, Reginster J-YL. Radiologic features poorly predict clinical outcomes in knee osteoarthritis. Scand J Rheumatol 2002;31:13-16.
112. Hamerman D. The biology of osteoarthritis. N Engl J Med 1989;320:1322-1330.
113. Noyszewski EA, Wroblewski K, Dodge GR, Kudchodkar S, Beers J, Sarma AV, Reddy R. Preferential incorporation of glucosamine into the galactosamine moieties of chondroitin sulfates in articular cartilage explants. Arthritis Rheum 2001;44:1089-1095.
114. Setnikar I, Giachetti C, Zanolo G. Absorption, distribution and excretion of radioactivity after a single intravenous or oral administration of [ 14 C] glucosamine to the rat. Pharmatherapeutica 1984;3:538-550.
115. Setnikar I, Rovati LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneim Forsch 2001;51:699-725.
116. Setnikar I, Giacchetti C, Zanolo G. Pharmacokinetics of glucosamine in the dog and in man. Arzneim Forsch 1986;36:729-735.
117. Setnikar I, Palumbo R, Canali S, Zanolo G. Pharmacokinetics of glucosamine in man. Arzneim Forsch 1993;43:1109-1113.
118. Hoffer LJ, Kaplan LN, Hamadeh MJ, Grigoriu AC, Baron M. Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism . 2001;50:767-770.
119. Conte A, Volpi N, Palmieri L, Bahous I, Ronca G. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneim Forsch 1995;45:918-925.
120. Palmieri L, Conte A, Giovannini L, Lualdi P, Ronca G. Metabolic fate of exogenous chondroitin sulfate in the experimental animal. Arzneim Forsch 1990;40:319-323.
121. Dohlman CH. The fate of the sulfate group of chondroitin sulfate after administration to rats. Acta Physiol Scand 1956;37:220-234.
122. Andermann G, Dietz M. The influence of route of administration on the bioavailability of an endogenous macromolecule: Chondroitin sulfate (CSA). Eur J Drug Metab Pharmacokinet 1982; 7:11 -16.
123. Dziewiatkowski DD. Some aspects of the metabolism of chondroitin sulfate- 35 S in the rat. J Biol Chem 1956;223:239-249.
124. Konador A, Kawiak J. Distribution of radioactivity in the mouse organism after administration of 35 S-chondroitin sulfate. Folia Biol ( Krakow ) 1976;24:177-190.
125. Morrison M. Therapeutic applications of chondroitin 4-sulfate, appraisal of biological properties. Folia Angiol 1977;25:225-232.
126. Baici A, Horler D, Moser B, Hofer HO, Fehr K, Wagenhauser FJ. Analysis of glycosaminoglycans in human serum after oral administration of chondroitin sulfate. Rheumatol Int 1992;12:81-88.
127. Murata K. Absorption, distribution, metabolism and excretion of acid mucopolysaccharides administered to animals and patients. In: Morrison LM, Schjeide OA (eds.). Coronary Heart Disease and the Mucopolysaccharides (Glycosaminoglycans) . Charles C Thomas, Springfield , IL , 1974, pp. 109-127.
128. Conte A, de Bernardi M, Palmieri L, Lualdi P, Mautone G, Ronca G. Metabolic fate of exogenous chondroitin sulfate in man. Arzneim Forsch 1991;41:768-772.
129. Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf ® ) and its constituents in healthy male volunteers. Osteoarthritis Cartilage 2002;10:768-777.
130. Gross D. Orale Chondroitinsulfatmedikation zur Behandlung von Arthrosen. [Oral chondroitin sulfate medication for the treatment of osteoarthritis.] Therapiewoche 1983;33:4238-4244.
131. Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 1998;6(Suppl. A):14-21.
132. Gouze JN, Bordji K, Gulberti S, Terlain B, Netter P, Magdalou J, Fournel-Gigleux S, Ouzzine M. Interleukin-1β down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1beta-mediated effects in rat chondrocytes. Arthritis Rheum 2001;44:351-360.
• Gouze JN, Bianchi A, Becuwe P, Dauca M, Netter P, Magdalou J, Terlain B, Bordji K. Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-κB pathway. FEBS Lett 2002;510:166-170.
134. Fenton JI, Chlebek-Brown KA, Caron JP, Orth MW. Effect of glucosamine on interleukin-1-conditioned articular cartilage. Equine Vet J Suppl 2002;34:219-223.
135. Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP, Orth MW. Glucosamine HCl reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage 2000;8:258-265.
136. Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP, Orth MW. The effects of glucosamine derivatives on equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage 2000;8:444-451.
137. Orth MW, Peters TL, Hawkins JN. Inhibition of articular cartilage degradation by glucosamine-HCl and chondroitin sulphate. Equine Vet J Suppl 2002;34:224-229.
138. Piperno M, Reboul P, Hellio Le Graverand MP, Peschard MJ, Annefeld M, Richard M, Vignon E. Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cartilage 2000;8:207-212.
139. Sandy JD, Gamett D, Thompson V, Verscharen C. Chondrocyte-mediated catabolism of aggrecan: Aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J 1998;335:59-66.
140. Bassleer C, Rovati L, Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartilage 1998;6:427-434.
141. Setnikar I, Pacini MA, Revel L. Antiarthritic effects of glucosamine sulfate studied in animal models. Arzneim Forsch 1991;41:542-545.
142. Bassleer C, Henrotin Y, Franchimont P. In-vitro evaluation of drugs proposed as chondroprotective agents. Int J Tissue React 1992;14:231-241.
143. Piperno M, Reboul P, Hellio Le Graverand MP, Peschard MJ, Annefeld M, Richard M, Vignon E. Osteoarthritic cartilage fibrillation is associated with a decrease in chondrocyte adhesion to fibronectin . Osteoarthritis Cartilage 1998;6:393-399.
144. Oegema TR Jr, Deloria LB, Sandy JD, Hart DA. Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits. Arthritis Rheum 2002;46:2495-2503.
145. Dean DD, Martel-Pelletier J, Pelletier J-P, Howell DS, Woessner JF Jr. Evidence for metalloproteinase and metalloproteinase inhibitor (TIMP) imbalance in human osteoarthritis. J Clin Invest 1989;84:678-685.
146. Pelletier J-P, Roughley P, Di Battista JA, McCollum R, Martel-Pelletier J. Are cytokines involved in osteoarthritic pathophysiology? Semin Arthritis Rheum 1991;20(Suppl. 2):12-25.
147. Roden L. Effect of hexosamines on the synthesis of chondroitin sulphuric acid in vitro . Arkiv Kemi 1956;10:345-352.
148. de Mattei M, Pellati A, Pasello M, de Terlizzi F, Massari L, Gemmati D, Caruso A. High doses of glucosamine-HCl have detrimental effects on bovine articular cartilage explants cultured in vitro. Osteoarthritis Cartilage 2002;10:816-825.
149. Anderson CC, Cook JL, Kreeger JM, Tomlinson JL, Wagner-Mann CC. I n vitro effects of glucosamine and acetylsalicylate on canine chondrocytes in three-dimensional culture. Am J Vet Res 1999;60:1546-1551.
150. Hua J, Sakamoto K, Nagaoka I. Inhibitory actions of glucosamine, a therapeutic agent for osteoarthritis, on the functions of neutrophils. J Leukoc Biol 2002;71:632-640.
151. Ma L, Rudert WA, Harnaha J, Wright M, Machen J, Lakomy R, Qian S, Lu L, Robbins PD, Trucco M, Giannoukakis N. Immunosuppressive effects of glucosamine. J Biol Chem 2002;277:39343-39349.
152. Sobal G, Sinzinger H. Binding of [ 99m Tc]chondroitin sulfate to scavenger receptors on human chondrocytes as compared to binding of oxidized [ 125 I]LDL on human macrophages. J Recept Signal Transduct Res 2002;22:459-470.
153. Bassleer CT , Combal J-PA, Bougaret S, Malaise M. Effects of chondroitin sulfate and interleukin-1 β on human articular chondrocytes cultivated in clusters. Osteoarthritis Cartilage 1998;6:196-204.
154. Bobacz K, Erlacher L, Graninger WB. Der Einfluß von Condrosulf ® (Natriumchondroitinsulfat) auf die Proteoglykansynthese und Zellproliferation osteoarthrotischer humaner und juveniler boviner Gelenksknorpelzellen – eine In-vitro-Untersuchung. [The effect of Condrosulf (sodium chondroitin sulfate) on proteoglycan synthesis by human osteoarthritic an bovine juvenile articular cartilage chondrocytes–an in vitro study] Acta Med Austriaca 2002;29:20-25.
155. Bollet AJ. Stimulation of protein-chondroitin sulfate synthesis by normal and osteoarthritic articular cartilage. Arthritis Rheum 1968;11:663-673.
156. Nevo Z, Dorfman A. Stimulation of chondromucoprotein synthesis in chondrocytes by extracellular chondromucoprotein. Proc Natl Acad Sci USA 1972;69:2069-2072.
157. Schwartz NB, Dorfman A. Stimulation of chondroitin sulfate proteoglycan production by chondrocytes in monolayer. Connect Tissue Res 1975;3:115-122.
158. Nerucci F, Fioravanti A, Cicero MR, Collodel G, Marcolongo R. Effects of chondroitin sulfate and interleukin-1β on human chondrocyte cultures exposed to pressurization: A biochemical and morphological study. Osteoarthritis Cartilage 2000;8:279-287.
159. Baici A, Lang A. Cathepsin B secretion by rabbit articular chondrocytes: Modulation by cycloheximide and glycosaminoglycans. Cell Tissue Res 1990;259:567-573.
160. Conrozier T. La mort des chondrocytes articulaires. Mecanisme et protection. [Death of articular chondrocytes. Mechanisms and protection] Presse Med 1998;27:1859-1861.
161. Reveliere D, Mentz F, Merle-Beral H, Chevalier X. Protective effect of chondroitin 4&6 sulfate on apoptosis of rabbit articular chondrocytes: Preliminary results. Litera Rheumatologica 1999; 24:15-20.
162. Uebelhart D, Thonar EJ, Zhang J, Williams JM. Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthritis Cartilage 1998;6(Suppl A):6-13.
163. Omata T, Itokazu Y, Inoue N, Segawa Y. Effects of chondroitin sulfate-C on articular cartilage destruction in murine collagen-induced arthritis. Arzneim Forsch 2000;50:148-153.
164. Omata T, Segawa Y, Itokazu Y, Inoue N, Tanaka Y. Effects of chondroitin sulfate-C on bradykinin-induced proteoglycan depletion in rats. Arzneim Forsch 1999;49:577-581.
165. Baici A, Bradamante P. Interaction between human leukocyte and chondroitin sulfate. Chem Biol Interactions 1984;51:1-11.
166. Bartolucci C, Cellai L, Iannelli MA, Lamba D, Liverani L, Mascellani G, Perola E. Inhibition of human leukocyte elastase by chemically and naturally oversulfated galactosaminoglycans. Carbohydr Res 1995;276:401-408.
167. Soldani G, Romagnoli J. Experimental and clinical pharmacology of glycosaminoglycans (GAGs). Drugs Exptl Clin Res 1991;17:81-85.
168. Antonilli L, Paroli E. Role of the oligosaccharide inner core in the inhibition of human leukocyte elastase by chondroitin sulfates. Int J Clin Pharm Res 1993;13(Suppl):11-17.
169. Volpi N. Inhibition of human leukocyte elastase activity by chondroitin sulfates. Chem Biol Interact 1997;105:157-167.
170. Rachmilewitz J, Tykocinski ML. Differential effects of chondroitin sulfates A and B on monocyte and B-cell activation: Evidence for B-cell activation via a CD44-dependent pathway. Blood 1998;92:223-229.
171. Avila JL. The influence of the type of sulphate bond and degree of sulphation of glycosaminoglycans on their interaction with lysosomal enzymes. Biochem J 1978;171:489-491.
172. Bartolucci C, Cellai L, Corradini C, Corradini D, Lamba D, Velona I. Chondroprotective action of chondroitin sulfate. Competitive action of chondroitin sulfate on the digestion of hyaluronan by bovine testicular hyaluronidase. Int J Tiss React 1991;13:311-317.
173. Braham R, Dawson B, Goodman C. The effect of glucosamine supplementation on people experiencing regular knee pain. Br J Sports Med 2003;37:45-49.
174. Rindone JP, Hiller D, Collacott E, Nordhaugen N, Arriola G. Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med 2000;172:91-94.
175. Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999;26:2423-2430.
176. Drovanti A, Bignamini AA, Rovati AL. Therapeutic activity of oral glucosamine sulfate in osteoarthrosis: a placebo-controlled double-blind investigation. Clin Ther 1980;3:260-272.
177. Rovati LC. Clinical research in osteoarthritis: Design and results of shot-term and long-term trials with disease-modifying drugs. Int J Tiss Reac 1992;14:248-251.
178. Noack W, Fischer M, Forster KK, Rovati LC, Setnikar I. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage 1994;2:51-59.
179. Pujalte JM, Llavore EP, Ylescupidez FR. Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis. Curr Med Res Opin 1980;7:110-114.
180. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis. A 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002;162:2113-2123.
181. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE, Gossett C. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-256.
182. Tapadinhas MJ, Rivera IC, Bignamini AA. Oral glucosamine sulphate in the management of arthrosis: report on a multi-centre open investigation in Portugal. Pharmatherapeutica 1982;3:157-168.
183. Bohmer D, Ambrus P, Szogy A, Haralambie G. Die Chondropathia patellae des jugendlichen Sportles. [Chondropathia patellae in young athletes.] Therapiewoche 1982;32:4897-4901.
184. Müller-Faßbender H, Bach GL, Haase W, Rovati LC, Setnikar I. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage 1994;2:61-69.
185. Qiu GX, Gao SN, Giacovelli G, Rovati L, Setnikar I. Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Arzneim Forsch 1998;48:469-474.
186. Vas AL. Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients. Curr Med Res Opin 1982;8:145-149.
187. Thie NM, Prasad NG, Major PW. Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: a randomized double blind controlled 3 month clinical trial. J Rheumatol 2001;28:1347-1355.
188. Towheed TE, Anastassiades TP, Shea B, Houpt J, Welch V, Hochberg MC. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2001;CD002946.
189. Häuselmann HJ. Nutripharmaceuticals for osteoarthritis. Best Pract Res Clin Rheumatol 2001;15:595-607.
190. Kayne SB, Wadeson K, MacAdam A. Is glucosamine an effective treatment for osteoarthritis? A meta-analysis. Pharm J 2000;265:759-763.
191. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: A systematic quality assessment and meta-analysis. JAMA 2001;283:1469-1475.
192. Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 1998;6 (Suppl. A):31-36.
193. Uebelhart D, Thonar EJ, Delmas PD, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1998;6 (Suppl. A):39-46.
194. Mathieu P. Progression radiologique de l’arthrose fémoro-tibiale interne dans la gonarthrose. Effet chondroprotecteur des chondroïtines-sulfates ACS4-ACS6. [Radiological progression of internal femoro-tibial osteoarthritis in gonarthrosis. Chondro-protective effect of chondroitin sulfates ACS4-ACS6] Presse Med 2002;31:1386-1390.
195. Bourgeois P, Chales G, Dehais J, Delcambre B, Kuntz JL, Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo. Osteoarthritis Cartilage 1998;6 (Suppl. A):25-30.
196. L’Hirondel JL. Klinische Doppelblind-Studie mit oral verabreichtem Chondroitinsulfat gegen Placebo bei der tibiofemoralen Gonarthrose (125 Patienten). [Clinical double-blind study with orally administered chondroitin sulfate versus placebo for tibiofemoral osteoarthritis of the knee (125 patients).] Litera Rheumatol 1992;14:77-84.
197. Conrozier T, Vignon E. Die Wirkung von Chondroitinsulfat bei der Behandlung der Hüftgelenksarthrose eine Doppelblindstudie gegen placebo. [The effectiveness of chondroitin sulfate in the treatment of hip joint osteoarthritis: A double-blind study versus placebo.] Litera Rheumatol 1992;14:69-75.
198. Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis Cartilage 1998;6 (Suppl. A):37-38.
199. Henry-Launois B. Evaluation of the use and financial impact of Chondrosulf 400 ® in current medical practice. Litera Rheumatol 1999;24:49-51.
200. Leeb BF, Petera P, Neumann K. Ergebnisse einer multizentrischen Anwendungsbeobachtung von Chondroitinsulfat (Condrosulf ® ) beiArthrosen der Finger-, Knie- und Hüftgelenke. [Results of a multicenter study of chondroitin sulfate (Condrosulf ® ) use in arthroses of the finger, knee and hip joints] Wien Med Wochenschr 1996;146:609-614.
201. Conrozier T. Les chondroitines sulfates (CS 4&6): Schema d’utilisation et impact economique. [Chondroitin sulfates (CS 4&6): practical applications and economic impact] Presse Med 1998;27:1866-1868.
202. Serni U, Marin G, Matucci A, Dal Pozzo GC, Petacchi D, Naldoni GC, Taverni N. New joint imaging tools in osteoarthritis. I: Validation and preliminary experience with GGGS treatment. Int J Pharmacol Res 1993;13(Suppl):43-47.
203. Pipitone V, Ambanelli U, Cervini C, Ligniere GC, Ugo GT, Ferraris M, Marcolongo R, Megale F, Serni U, Trotta F, Martino F. A multicenter, triple-blind study to evaluate galactosaminoglucuronoglycan sulfate versus placebo in patients with femorotibial gonarthritis. Cur Ther Res 1992;52:608-638.
204. Riccieri V, Spadaro M, Taccari E. Osservazioni preliminari sell’attivita terapeutica e la tollerabilita del galattosaminoglicuronoglican solfato (GAGGs) nella terapia dell’artrosi dell’anca e dei ginocchio. Valutazione aperta di due differenti preparazioni farmaceutiche. Farmaci Terapia 1991; 8(1-2):62-65.
205. Anonymous. Etude multicentrique europeenne sur l’utilisation du sulfate de chondroitine dans la gonarthrose: Nouveau regard sur les resultants biochimiques et radiologiques. [European multicenter study on effectiveness of chondroitin sulfate in gonarthrosis: a new look at biochemical and radiologic results] Presse Med 2000;29(27 Suppl):15-18.
206. Malaise M, Marcolongo R, Uebelhart D, Vignon E. Efficacy and tolerability of 800 mg oral chondroitin 4&6 sulfate in the treatment of knee osteoarthritis: A randomised, double-blind, multicentre study versus placebo. LiteraRheumatologica 1999; 24:31-42.
207. Conrozier T. Les traitements anti-arthrosiques: Efficacite et tolerance des chondroitines sulfates (CS 4&6). [Anti-arthrosis treatments: Efficacy and tolerance of chondroitin sulfates (CS 4&6)] Presse Med 1998;27:1862-5.
208. Morreale P, Manopulo R, Galati M, Boccanera L, Saponati G, Bocchi L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996;23:1385-1391.
209. Alekseeva LI, Mednikov BL, Piiavskii SA, Nasonova VA, Soldatov DG. Фармакоэкономические Аспекты Применения Структума При Остеоартроэе. [Pharmacoeconomic aspects of use of structum in osteoarthrosis] Ter Arkh 2001;73:90-92.
210. Thilo G. Etude de 35 cas d’arthrose traités par l’acide chondroïtine sulfurique. [A study of 35 cases of arthrosis treated with chondroitin sulfuric acid.] Schweiz Rundschau Med (Praxis) 1977; 66:1696-1699.
211. Nasonova VA, Alekseeva LI, Arkhangel’skaia GS, Davydova AF, Karmil’tseva EA, Kogan KM, Mazurov VI, Rebrov AP, Riabitseva OF, Shemerovskaia TG, Shmidt EI, Iakushin SS, Soldatov DG. Итоги Многоцентрового Клинического Исследования Препарата Структум В России. [Results of the multicenter clinical trial of structum preparation in Russia] Ter Arkh 2001;73:84-7.
212. Charlot J, Dreiser RL, Loyau G, Masounabe-Puyanne A, Mazieres B, Menkes CJ, Valat JP. Le Chondroitine sulfate dans le traitement de la gonarthrose et de la coxarthrose. Resultats a 5 mois, d’une etude prospective multicentrique, controlee, en double aveugle, versus placebo. [Chondroitin sulfate for the treatment of coxarthrosis and gonarthrosis. A 5-month, prospective, multicenter, placebo-controlled, double-blind trial.] Rev Rhum Mal Osteoartic 1992;59:1-7.
213. Mazieres B, Combe B, Van AP, Tondut J, Grynfeltt M. Chondroitin sulfate in osteoarthritis of the knee: A prospective, double blind, placebo controlled multicenter clinical study. J Rheumatol 2001;28:173-181.
214. Rovetta G, Monteforte P. Galactosaminoglycuronglycan sulfate in erosive osteoarthritis of the hands: Early diagnosis, early treatment. Int J Tiss Reac 1996; 18(1):43-46.
215. Rovetta G, Monteforte P, Molfetta G, Balestra V. Chondroitin sulfate in erosive osteoarthritis of the hands. Int J Tissue React 2002;24:29-32.
216. Leeb BF, Schweitzer H, Montag K, Smolen JS. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000;27:205-211.
217. du Souich P, Verges J. Simple approach to predict the maximal effect elicited by a drug when plasma concentrations are not available or are dissociated from the effect, as illustrated with chondroitin sulfate data. Clin Pharmacol Ther 2001;70:5-9.
218. Nakamura H, et al. [The effect of combined glucosamine/chondroitin formula on osteoarthritis and the concentration of serum YKL-40 (abstract).] J Jpn Orthop Assoc 2001;75:S623.
219. Lippiello L, Woodward J, Karpman R, Hammad TA. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop 2000;381:229-240.
220. Das A Jr, Hammad TA. Efficacy of a combination of FCHG49™ glucosamine hydrochloride, TRH122™ low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage 2000;8:343-350.
221. Leffler CT , Philippi AF, Leffler SG, Mosure JC, Kim PD. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study. Mil Med 1999;164:85-91.
222. Nguyen P, Mohamed SE, Gardiner D, Salinas T. A randomized double-blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio 2001;19:130-139.
223. Shankland WE 2nd. The effects of glucosamine and chondroitin sulfate on osteoarthritis of the TMJ: a preliminary report of 50 patients. Cranio 1998;16:230-235.
224. Anonymous. Glucosamine sulfate. Altern Med Review 1999;4:193-195.
225. Caron JP, Peters TL, Hauptman JG, Eberhart SW, Orth MW. Serum concentrations of keratan sulfate, osteocalcin, and pyridinoline crosslinks after oral administration of glucosamine to standardbred horses during race training. Am J Vet Res 2002;63:1106-1110.
226. Vetter G. Lokale therapie der arthrosen mit glukoaminen (Dona 200). [Local therapy of arthroses with glucosamines (Dona 200).] Munch Med Wochenschr 1969;111:1499-1502.
227. Crolle G, D’Este E. Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation. Curr Res Med Opinion 1980; 7(2):104-109.
228. D’Ambrosio E, Casa B, Bompani R, Scali G, Scali M. Glucosamine sulphate: a controlled clinical investigation in arthrosis. Pharmatherapeutica 1981; 2(8):504-508.
229. Echard BW, Talpur NA, Funk KA, Bagchi D, Preuss HG. Effects of oral glucosamine and chondroitin sulfate alone and in combination on the metabolism of SHR and SD rats. Mol Cell Biochem 2001;225:85-91.
• Shikhman AR , Kuhn K, Alaaeddine N, Lotz M. N -Acetylglucosamine prevents IL-1β-mediated activation of human chondrocytes. J Immunol 2001;166:5155-5160.
• Anonymous. Effets benefiques de Chondrosulf ® 400 sur la douleur et la fonction articulaire dans l’arthrose: Meta-analyse. [Beneficial effects of Chondrosulf 400 on pain and articular function in arthrosis: a meta-analysis] Presse Med 2000;29(27 Suppl):19-20.